var title_f17_37_18000="Norm ad sagital knee MRI";
var content_f17_37_18000=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F51776&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F51776&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Normal patellar tendon",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 384px; height: 384px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This sagittal proton density magnetic resonance image of the knee demonstrates the normal low signal of an intact patellar tendon (arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Shahla Modarresi, MD and Cecilia M Jude, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_37_18000=[""].join("\n");
var outline_f17_37_18000=null;
var title_f17_37_18001="Nonossifying fibroma prox tibia";
var content_f17_37_18001=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F79406&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F79406&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Nonossifying fibroma of the proximal tibia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 410px; height: 503px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This eccentrically placed, well-defined radiolucent lesion displays typical features of a slowly developing neoplasm, which is distorted with long bone growth (arrow). Its length far exceeds its width.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Yochum TR, Rowe LJ. Yochum and Rowe's Essentials of Skeletal Radiology, Third Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2004. Copyright &copy; 2004 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_37_18001=[""].join("\n");
var outline_f17_37_18001=null;
var title_f17_37_18002="Rounded atelectasis Low";
var content_f17_37_18002=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F68171&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F68171&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Histopathology of rounded atelectasis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 231px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Low power photomicrograph shows invagination of thickened visceral pleura (arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     From Colby TV, Koss MN, Travis WD. Tumors of the Lower Respiratory Tract. Armed Forces Institute of Pathology, Washington, DC.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_37_18002=[""].join("\n");
var outline_f17_37_18002=null;
var title_f17_37_18003="Lymphangioma tongue";
var content_f17_37_18003=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F65778&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F65778&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Infected lymphangioma of the tongue",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 360px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Fleisher GR, MD, Ludwig W, MD, Baskin MN, MD. Atlas of Pediatric Emergency Medicine. Philadelphia: Lippincott Williams &amp; Wilkins, 2004. Copyright &copy; 2004 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_37_18003=[""].join("\n");
var outline_f17_37_18003=null;
var title_f17_37_18004="Membranous VSD with double chambered RV still frame";
var content_f17_37_18004=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F52909&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F52909&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 565px\">",
"   <div class=\"ttl\">",
"    Membranous VSD with double chambered RV still frame",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 545px; height: 368px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Paired subcostal parasagittal images with and without superimposed color flow mapping, demonstrating narrowing of the right ventricular outflow tract (RVOT) by muscle bundles (thick arrows), positioned cephalad to the ventricular septal defect (VSD) (thin arrow), dividing the right ventricle into a caudal high pressure chamber and a more cephalad low pressure chamber.",
"    <div class=\"footnotes\">",
"     PA: pulmonary artery; LVOT: left ventricular outflow tract; LA: left atrium; RV: right ventricle; IVS: intraventricular septum; thin arrow: VSD.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_37_18004=[""].join("\n");
var outline_f17_37_18004=null;
var title_f17_37_18005="Nafarelin: Patient drug information";
var content_f17_37_18005=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Nafarelin: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/61/26580?source=see_link\">",
"     see \"Nafarelin: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F199096\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Synarel&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F199097\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Synarel&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10016918\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691832",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat endometriosis.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691363",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to delay puberty in children who are maturing too early.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10016917\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to nafarelin or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703865",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have vaginal bleeding and have not been to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10016922\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697753",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use care if you have risks for heart disease (high blood pressure, high cholesterol, overweight, high blood sugar (diabetes), cigarette smoking, man older than 40 years of age, other family members with early heart disease, woman after change of life). Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697315",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have soft, brittle bones (osteoporosis), talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697754",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use care if you have risks for soft, brittle bones called osteoporosis (alcohol use, cigarette smoking, other family members with brittle bones, taking drugs to treat seizures, taking steroids).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698406",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have a bone density test if you are taking this drug for more than 6 months or if you have risks for soft, brittle bones (osteoporosis).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696919",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use a nose decongestant spray within 2 hours after using this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696708",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Birth control pills and other hormone-based birth control may not work to stop pregnancy. Use 2 kinds of birth control while taking this drug.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10016923\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698094",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Flushing. Wearing layers of clothes or summer clothes and staying in cool places may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696435",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Pimples (acne).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698385",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Vaginal irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Nose irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698316",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Runny nose.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698390",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Weak bones with long-term use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698036",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Emotional ups and downs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698236",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Mood changes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697963",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in sex ability.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698293",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Ovarian cysts may rarely happen in the first 2 months of therapy.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10016925\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698626",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699040",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Bad nose irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699086",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight, eye pain, or irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698672",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For women, still having a period.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698670",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For women, if you get pregnant while taking this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698963",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       More trips to the bathroom, more thirst, or weight loss.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10016920\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696130",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To gain the most benefit, do not miss doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696185",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use as you have been told, even if you are feeling better.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694774",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take this drug by mouth. Use in your nose only. Keep out of your mouth and eyes (may burn).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694567",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Blow your nose before use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694745",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not sneeze during or right after using this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694584",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check your spray use with your doctor at each visit. Read and follow the facts on how to use the spray. Make sure you use the spray the right way.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10016921\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696583",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696485",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use 2 doses or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10016926\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10016927\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699681",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Read the package insert for more details.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11505 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-201.211.0.116-3ACED954D5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_37_18005=[""].join("\n");
var outline_f17_37_18005=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199096\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199097\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016918\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016917\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016922\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016923\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016925\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016920\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016921\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016926\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016927\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?25/61/26580?source=related_link\">",
"      Nafarelin: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_37_18006="CT scan rib fractures";
var content_f17_37_18006=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RADIOL%2F83646&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RADIOL%2F83646&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 616px\">",
"   <div class=\"ttl\">",
"    CT scan rib fractures",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 596px; height: 509px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The patient is a 41-year-old man who sustained trauma and was complaining of left sided back pain. The findings on plain film are not obvious (A). The CT scan through the lower chest in the axial plane (B) reveals an obvious minimally displaced left sided posterior rib fracture (white arrow) which is magnified in image&nbsp;C. There is an associated small effusion or hemothorax (red arrow), minor atelectasis at the left base (yellow arrow), and a small amount of extrapleural hemorrhage (green arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_37_18006=[""].join("\n");
var outline_f17_37_18006=null;
var title_f17_37_18007="Chronic complications of the short bowel syndrome in adults";
var content_f17_37_18007=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Chronic complications of the short bowel syndrome in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/37/18007/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/37/18007/contributors\">",
"     Jon A Vanderhoof, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/37/18007/contributors\">",
"     Rosemary J Pauley-Hunter, NP-C, MS, RN",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/37/18007/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/37/18007/contributors\">",
"     J Thomas LaMont, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/37/18007/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/37/18007/contributors\">",
"     Shilpa Grover, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?17/37/18007/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 13, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic complications of short bowel syndrome include liver and biliary disease associated with parenteral nutrition, malabsorptive nutritional abnormalities including metabolic bone disease, small bowel bacterial overgrowth induced arthritis and colitis, enteric hyperoxaluria, and D-lactic acidosis. Other complications related to parenteral nutrition such as central line sepsis and catheter breakage also are common until the parenteral nutrition phase has ceased [",
"    <a class=\"abstract\" href=\"UTD.htm?17/37/18007/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Patients with intractable complications may be candidates for small bowel transplantation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/29/1497?source=see_link\">",
"     \"Overview of intestinal and multivisceral transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The chronic complications of short bowel syndrome will be reviewed here. An overview of the management of short bowel syndrome and its pathogenesis are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/6/44136?source=see_link\">",
"     \"Management of the short bowel syndrome in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/56/30601?source=see_link\">",
"     \"Pathophysiology of the short bowel syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     HEPATOBILIARY DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with short bowel syndrome who require long-term parenteral nutrition are at risk for the development of liver disease and cholelithiasis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Liver disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Liver disease associated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/40/42628?source=see_link\">",
"     total parenteral nutrition",
"    </a>",
"    can be a significant problem. The changes range from steatosis due to excessive caloric administration in older children and adults to steatohepatitis and cholestasis [",
"    <a class=\"abstract\" href=\"UTD.htm?17/37/18007/abstract/3\">",
"     3",
"    </a>",
"    ]. Cholestatic liver dysfunction may lead to cirrhosis and portal hypertension, and is a major indication for combined",
"    <span class=\"nowrap\">",
"     liver/intestine",
"    </span>",
"    transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?17/37/18007/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cholestatic liver disease is more common in patients with short bowel syndrome than in many other patients on parenteral nutrition [",
"    <a class=\"abstract\" href=\"UTD.htm?17/37/18007/abstract/5\">",
"     5",
"    </a>",
"    ]. The degree and severity of the liver disease appears to be related in part to recurrent sepsis including catheter sepsis, bacterial translocation from overgrowth in the small intestine, and cholangitis. Lack of enteral feeding also may contribute by leading to reduced gut hormone secretion, reduced bile flow, and biliary stasis.",
"   </p>",
"   <p>",
"    The incidence of liver disease in adult patients receiving long-term parenteral nutrition was illustrated in a cohort study that included 90 patients with permanent intestinal failure [",
"    <a class=\"abstract\" href=\"UTD.htm?17/37/18007/abstract/5\">",
"     5",
"    </a>",
"    ]. Chronic cholestasis was observed in 58 patients (65 percent) after a median of six months. Complicated liver disease (defined as extensive portal fibrosis or cirrhosis, a serum bilirubin &ge;3.5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (60",
"    <span class=\"nowrap\">",
"     &micro;mol/L)",
"    </span>",
"    for at least one month, encephalopathy, or complications related to portal hypertension) developed in 37 patients (42 percent) after a median of 17 months. On multivariate analysis, cholestasis was significantly associated with a bowel remnant shorter than 50 cm, and a parenteral lipid intake of 1",
"    <span class=\"nowrap\">",
"     g/kg",
"    </span>",
"    of body weight per day or more (omega-6 rich long-chain triglycerides). Complicated liver disease was associated with chronic cholestasis and lipid parenteral intake of 1",
"    <span class=\"nowrap\">",
"     g/kg",
"    </span>",
"    per day or more; it adversely affected survival only in patients older than 41.",
"   </p>",
"   <p>",
"    In contrast to the findings discussed above, long-term data from other groups suggest that life-threatening liver disease caused by TPN is rare; however, when it occurs, as noted above, it is most often due to one or more episodes of sepsis, complications of multiple-drug therapy and bacterial overgrowth [",
"    <a class=\"abstract\" href=\"UTD.htm?17/37/18007/abstract/6\">",
"     6",
"    </a>",
"    ]. The differences in outcomes in these reports may be due to variable uses of aggressive enteral therapy, which is thought to be hepatic protective.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Prevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;Optimal methods for preventing or retarding the development of liver disease have not been established. The study discussed above [",
"    <a class=\"abstract\" href=\"UTD.htm?17/37/18007/abstract/5\">",
"     5",
"    </a>",
"    ] supports a strategy of delivering less than 1",
"    <span class=\"nowrap\">",
"     g/kg",
"    </span>",
"    per day of omega-6 rich long-chain triglycerides in older adult patients. Other preventative strategies have been suggested:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Intestinal rehabilitation programs can prevent liver disease by a program designed to promote intestinal motility and discourage bacterial translocation [",
"      <a class=\"abstract\" href=\"UTD.htm?17/37/18007/abstract/7\">",
"       7",
"      </a>",
"      ]. Important elements of this program were aggressive use of enteral nutrition, control of small bowel bacterial overgrowth, and prevention of catheter sepsis. However, comprehensive coordinated care and effective use of diet to enhance absorption and adaptation are likely important factors here.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/5/12373?source=see_link\">",
"       Ursodeoxycholic acid",
"      </a>",
"      (UDCA) is beneficial in several chronic cholestatic liver diseases, particularly primary biliary cirrhosis and, to a lesser degree, primary sclerosing cholangitis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/32/43526?source=see_link\">",
"       \"Ursodeoxycholic acid in the treatment of primary biliary cirrhosis\"",
"      </a>",
"      .) In one series of seven children, for example, the administration of UDCA led to normalization of the biochemical signs of cholestasis; three children relapsed with temporary cessation and then improved following restitution of therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?17/37/18007/abstract/8\">",
"       8",
"      </a>",
"      ]. UDCA could be discontinued without recurrent cholestasis after the children were switched to enteral feedings. Studies in adults show less consistent benefits but usage in those with TPN liver disease has few side effects [",
"      <a class=\"abstract\" href=\"UTD.htm?17/37/18007/abstract/9,10\">",
"       9,10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Studies of fish oil based intralipid in children have demonstrated positive effects in preventing and reversing parenteral nutrition associated liver injury and use in adults is currently under investigation [",
"      <a class=\"abstract\" href=\"UTD.htm?17/37/18007/abstract/11-13\">",
"       11-13",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/18/18730?source=see_link&amp;anchor=H22#H22\">",
"       \"Parenteral nutrition-associated liver disease in infants\", section on 'Fish oil-based fat emulsions'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Gallstones",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with short bowel syndrome experience an increased incidence of gallstones [",
"    <a class=\"abstract\" href=\"UTD.htm?17/37/18007/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. One study of 84 patients with severe short bowel syndrome found asymptomatic gallstones in 44 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?17/37/18007/abstract/14\">",
"     14",
"    </a>",
"    ]. Cholelithiasis and biliary complications occur most often in patients with little or no oral intake [",
"    <a class=\"abstract\" href=\"UTD.htm?17/37/18007/abstract/16\">",
"     16",
"    </a>",
"    ]. As a result, some authorities recommend routine cholecystectomy in parenteral-nutrition dependent patients [",
"    <a class=\"abstract\" href=\"UTD.htm?17/37/18007/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The pathogenesis of cholelithiasis in patients with the short bowel syndrome is not completely understood. At least two factors may contribute:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Interruption of the enterohepatic circulation of bile acids by ileal resection results in a reduction in hepatic bile acid secretion and an altered composition of hepatic bile, which becomes supersaturated with respect to cholesterol.",
"     </li>",
"     <li>",
"      Diminished enteric hormonal stimulation of gallbladder contraction may lead to biliary stasis and the formation of biliary sludge.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     BACTERIAL OVERGROWTH",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bacterial overgrowth, defined as increased numbers and species of bacteria in the small intestine, may be especially problematic in patients with short bowel syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?17/37/18007/abstract/18\">",
"     18",
"    </a>",
"    ]. Bacterial growth in the normal bowel is controlled by gastric acid, pancreatic enzyme activity, enterocyte turnover, normal antegrade peristaltic activity in the small intestine, and the ileocecal valve. Compromise of one or both of the last two mechanisms is common in the short bowel syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?17/37/18007/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Many patients have no ileocecal valve, the primary means for preventing reflux of bacteria from the colon into the small intestine.",
"     </li>",
"     <li>",
"      Progressive dilatation of the small intestine as part of the adaptation response limits the efficacy of peristalsis in ridding the small intestine of bacteria.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In some instances, bacteria in excessive numbers may be present but may be doing no harm or causing no symptoms. It has been suggested that bacterial translocation may have beneficial effects on the acquired immune system and therefore conditions of bacterial overgrowth, which predispose to bacterial translocation, may in fact be beneficial [",
"    <a class=\"abstract\" href=\"UTD.htm?17/37/18007/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Generally, the excess bacteria may worsen the malabsorption associated with the short bowel syndrome. Bacterial deconjugation of bile acids diminishes the intestinal absorption of monoglycerides and fatty acids. In addition, an inflammatory response often ensues in the small intestine, damaging the absorptive surface and resulting in malabsorption and protein loss. These changes are manifested clinically by an increase in caloric requirement and weight loss. In more severe cases, colitis and ileitis may occur, which can resemble Crohn's disease, although a more diffuse inflammatory picture may be more common [",
"    <a class=\"abstract\" href=\"UTD.htm?17/37/18007/abstract/21\">",
"     21",
"    </a>",
"    ]. In addition, the enteritis can elicit an inflammatory cascade with resultant inflammatory arthritis. Mild to moderate enteritis associated with short bowel bacterial overgrowth delays weaning of parenteral nutrition and therefore requires attention.",
"   </p>",
"   <p>",
"    When overgrowth is suspected, the diagnosis of bacterial overgrowth may be made by glucose breath hydrogen testing. Dietary intervention involves use of a low carbohydrate diet to reduce the substrate available for bacterial metabolism. Antibiotic treatment is effective but in many cases requires repeated or cyclical dosing. Antiinflammatory drugs such as corticosteroids and salicylate products may be necessary in severe cases [",
"    <a class=\"abstract\" href=\"UTD.htm?17/37/18007/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Small bowel enterography should be performed to assess for bowel dilatation when a patient with short bowel syndrome regresses. The STEP (serial transverse enteroplasty) is a surgical procedure that has the potential to decrease bowel dilatation associated with bacterial overgrowth and at the same time increase overall intestinal length [",
"    <a class=\"abstract\" href=\"UTD.htm?17/37/18007/abstract/23\">",
"     23",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/50/28454?source=see_link\">",
"     \"Treatment of small intestinal bacterial overgrowth\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     NUTRIENT ABNORMALITIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nutrient deficiencies are common once patients have been weaned from parenteral nutrition. It is at this time that clinicians often forget to monitor carefully for nutrient deficiency states since, once parenteral nutrition is ceased, one can never be certain how much micronutrient absorption occurs. Long-term parenteral nutrition has also been associated with bone demineralization most likely due to nutrient deficiencies; thus patients should be monitored with dual energy x-ray absorptiometry (DEXA scanning) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/37/18007/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/6/44136?source=see_link\">",
"     \"Management of the short bowel syndrome in adults\"",
"    </a>",
"    .) There has been a suggestion that other factors besides nutrient deficiencies including excess fluoride consumption and deficiency of glucagon-like peptide-2 may be causative factors in the development of osteoporosis associated TPN [",
"    <a class=\"abstract\" href=\"UTD.htm?17/37/18007/abstract/26,27\">",
"     26,27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Certain divalent cations such as calcium and magnesium may be excreted in excess amounts if there is a considerable degree of fat malabsorption resulting in significant deficiencies of these nutrients.",
"     </li>",
"     <li>",
"      A large retrospective study identified that hyperglycemia occurring with TPN therapy in a group of inpatients is associated with higher risks of adverse outcomes independent of age, sex, body weight, presence of diabetes, and several other factors [",
"      <a class=\"abstract\" href=\"UTD.htm?17/37/18007/abstract/28\">",
"       28",
"      </a>",
"      ]. Tighter monitoring and control of blood sugars in patients on TPN is becoming a higher priority as the consequences of blood sugar fluctuations are becoming better identified.",
"     </li>",
"     <li>",
"      The use of fish oil supplemented parenteral nutrition high in omega 3 fatty acids has been explored as a mechanism to decrease the inflammatory response in postoperative patients and may also prove beneficial in those requiring long-term TPN [",
"      <a class=\"abstract\" href=\"UTD.htm?17/37/18007/abstract/29\">",
"       29",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A study in adult patients with short bowel syndrome three months after surgery demonstrated that continuous tube feeding (exclusively or in conjunction with oral feeding) significantly increased net absorption of lipids, proteins, and energy compared with oral feeding [",
"      <a class=\"abstract\" href=\"UTD.htm?17/37/18007/abstract/30\">",
"       30",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     HYPEROXALURIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Another potential problem in patients with fat malabsorption is enteric hyperoxaluria (except for those who do not have a colon in continuity with intestinal contents). The increase in oxalate absorption and subsequent excretion in this setting is due both to binding of free calcium to fatty acids in the intestinal lumen and to increased colonic permeability to small molecules such as oxalate induced by exposure of the colon to nonabsorbed bile salts [",
"    <a class=\"abstract\" href=\"UTD.htm?17/37/18007/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/53/33626?source=see_link\">",
"     \"Risk factors for calcium stones in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with malabsorption may have additional factors predisposing to stone formation other than increased oxalate excretion (which can be as high as 80 to 200 mg [0.9 to 2.2 mmol] per day) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/37/18007/abstract/31\">",
"     31",
"    </a>",
"    ]. The diarrheal fluid losses can lead both to a reduction in urine volume and, if the patient has a metabolic acidosis, a low urine pH and a marked decrease in citrate excretion; these changes can promote uric acid as well as calcium oxalate stone formation. The net effect in patients with partial ileal bypass for severe hyperlipidemia is that the incidence of kidney stones may be high as 4 percent per year [",
"    <a class=\"abstract\" href=\"UTD.htm?17/37/18007/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of enteric hyperoxaluria is directed toward diminishing intestinal oxalate absorption [",
"    <a class=\"abstract\" href=\"UTD.htm?17/37/18007/abstract/32\">",
"     32",
"    </a>",
"    ]. The initial regimen consists of a low oxalate diet, high fluid intake, potassium citrate to correct metabolic acidosis if present, and oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/32/42504?source=see_link\">",
"     calcium carbonate",
"    </a>",
"    (1 to 4",
"    <span class=\"nowrap\">",
"     g/day)",
"    </span>",
"    to bind oxalate in the intestinal lumen. Although some of the calcium is absorbed, there is a proportionately greater fall in oxalate excretion.",
"   </p>",
"   <p>",
"    A low-fat, low-oxalate diet (",
"    <a class=\"graphic graphic_table graphicRef68231 \" href=\"UTD.htm?40/43/41661\">",
"     table 1",
"    </a>",
"    ) is another modality that may be helpful in this disorder by reducing the quantity of fatty acids and free oxalate in the colon. This diet, however, is often nutritionally inadequate in patients who have short bowel syndrome.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/33/36374?source=see_link\">",
"     Cholestyramine",
"    </a>",
"    , which binds both bile acids and oxalate, can also be used, but side effects may be limiting. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/2/38953?source=see_link\">",
"     \"Prevention of recurrent calcium stones in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     D-LACTIC ACIDOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;D-Lactic acidosis is another metabolic complication of short bowel syndrome most commonly seen in patients with an intact colon. The delivery of unabsorbed carbohydrate to the colon can lead to the production (and subsequent absorption) of D-lactate by gram-positive anaerobes; the lactate produced by normal metabolic processes is L-lactate [",
"    <a class=\"abstract\" href=\"UTD.htm?17/37/18007/abstract/33\">",
"     33",
"    </a>",
"    ]. Patients with short bowel syndrome frequently demonstrate chronically elevated serum concentrations of D-lactate [",
"    <a class=\"abstract\" href=\"UTD.htm?17/37/18007/abstract/34\">",
"     34",
"    </a>",
"    ]. They are usually asymptomatic, but carbohydrate loading can produce severe metabolic acidosis and a characteristic and recurrent neurologic syndrome consisting of confusion, cerebellar ataxia, and slurred speech. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/18/18723?source=see_link\">",
"     \"D-Lactic acidosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of D-lactic acidosis consists of acute",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/52/840?source=see_link\">",
"     sodium bicarbonate",
"    </a>",
"    administration to correct the acidemia and oral antimicrobial agents (such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/57/14229?source=see_link\">",
"     neomycin",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    ) to decrease the number of D-lactate producing organisms [",
"    <a class=\"abstract\" href=\"UTD.htm?17/37/18007/abstract/33\">",
"     33",
"    </a>",
"    ]. In some cases, however, antimicrobials can precipitate D-lactic acidosis in susceptible subjects by causing the overgrowth of D-lactate producing Lactobacilli [",
"    <a class=\"abstract\" href=\"UTD.htm?17/37/18007/abstract/35\">",
"     35",
"    </a>",
"    ]. A low carbohydrate diet (or the use of starch polymers rather than simple sugars) also is helpful, by diminishing carbohydrate delivery to the colon and decreasing bacterial fermentation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The long-term outcome of the short bowel syndrome was evaluated in a series that included 124 consecutive adults with nonmalignant causes leading to bowel resection who required home parenteral nutrition [",
"    <a class=\"abstract\" href=\"UTD.htm?17/37/18007/abstract/36\">",
"     36",
"    </a>",
"    ]. Survival at two and five years was 86 and 49 percent, respectively. A subsequent report demonstrated 88 and 78 percent survival at three and five years, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?17/37/18007/abstract/37\">",
"     37",
"    </a>",
"    ]. In both series, survival was significantly lower in those with &lt;50 cm of bowel. A study from the United Kingdom has identified that survival rates of home parenteral nutrition were better than those after intestinal transplant. In addition, mortality with home TPN tended to be related more to the underlying disease than to complications of parenteral nutrition [",
"    <a class=\"abstract\" href=\"UTD.htm?17/37/18007/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Intestinal transplantation has been advocated for patients with short bowel syndrome who are dependent on parenteral nutrition, especially those with multiple complications [",
"    <a class=\"abstract\" href=\"UTD.htm?17/37/18007/abstract/39\">",
"     39",
"    </a>",
"    ]. However, many studies have shown excellent quality of life and better five-year survival for those on parenteral nutrition than in those who have undergone intestinal transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?17/37/18007/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Chronic complications of short bowel syndrome include liver and biliary disease associated with parenteral nutrition, nutritional abnormalities, small bowel bacterial overgrowth induced arthritis and colitis, enteric hyperoxaluria, D-lactic acidosis, and catheter sepsis. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with short bowel syndrome who require long-term parenteral nutrition are at risk for the development of liver disease and cholelithiasis. Optimal methods for preventing or retarding the development of liver disease have not been established, although several have been proposed. We suggest aggressive enteral nutrition (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Hepatobiliary disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of bacterial overgrowth is usually made by breath testing. We suggest that such patients be treated with dietary interventions and antibiotics (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Dietary intervention involves use of a low carbohydrate diet to reduce the substrate available for bacterial metabolism. The choice of antibiotics is presented separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/50/28454?source=see_link\">",
"       \"Treatment of small intestinal bacterial overgrowth\"",
"      </a>",
"      .) Surgery may be an option in highly selected patients.",
"     </li>",
"     <li>",
"      Nutrient deficiencies are common once patients have been weaned from parenteral nutrition. We suggest that vitamin and mineral levels be measured at the time of discontinuation, then every three months for the first year, and then as needed based on the requirements for supplementation (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). We also suggest baseline and annual evaluation of bone density with dual energy X-ray absorptiometry (DEXA) (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Nutrient abnormalities'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Another potential problem in patients with significant fat malabsorption is enteric hyperoxaluria (except for those who do not have a colon in continuity with intestinal contents). We suggest that patients who have developed complications from hyperoxaluria (ie, kidney stones) be treated with a low oxalate diet, high fluid intake, potassium citrate to correct metabolic acidosis if present, and oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/32/42504?source=see_link\">",
"       calcium carbonate",
"      </a>",
"      (1 to 4",
"      <span class=\"nowrap\">",
"       g/day)",
"      </span>",
"      to bind oxalate in the intestinal lumen (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Hyperoxaluria'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/37/18007/abstract/1\">",
"      Pittiruti M, Hamilton H, Biffi R, et al. ESPEN Guidelines on Parenteral Nutrition: central venous catheters (access, care, diagnosis and therapy of complications). Clin Nutr 2009; 28:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/37/18007/abstract/2\">",
"      Ekema G, Milianti S, Boroni G. Total parenteral nutrition in patients with short bowel syndrome. Minerva Pediatr 2009; 61:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/37/18007/abstract/3\">",
"      Carter BA, Shulman RJ. Mechanisms of disease: update on the molecular etiology and fundamentals of parenteral nutrition associated cholestasis. Nat Clin Pract Gastroenterol Hepatol 2007; 4:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/37/18007/abstract/4\">",
"      Vanderhoof JA, Langnas AN. Short-bowel syndrome in children and adults. Gastroenterology 1997; 113:1767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/37/18007/abstract/5\">",
"      Cavicchi M, Beau P, Crenn P, et al. Prevalence of liver disease and contributing factors in patients receiving home parenteral nutrition for permanent intestinal failure. Ann Intern Med 2000; 132:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/37/18007/abstract/6\">",
"      Chung C, Buchman AL. Postoperative jaundice and total parenteral nutrition-associated hepatic dysfunction. Clin Liver Dis 2002; 6:1067.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/37/18007/abstract/7\">",
"      Torres C, Sudan D, Vanderhoof J, et al. Role of an intestinal rehabilitation program in the treatment of advanced intestinal failure. J Pediatr Gastroenterol Nutr 2007; 45:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/37/18007/abstract/8\">",
"      Spagnuolo MI, Iorio R, Vegnente A, Guarino A. Ursodeoxycholic acid for treatment of cholestasis in children on long-term total parenteral nutrition: a pilot study. Gastroenterology 1996; 111:716.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/37/18007/abstract/9\">",
"      Reinshagen K, Adams R, Trunk M, Wessel LM. The chronic liver disease in patients with short bowel syndrome: etiology and treatment. Minerva Pediatr 2009; 61:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/37/18007/abstract/10\">",
"      Raman M, Allard JP. Parenteral nutrition related hepato-biliary disease in adults. Appl Physiol Nutr Metab 2007; 32:646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/37/18007/abstract/11\">",
"      Puder M, Valim C, Meisel JA, et al. Parenteral fish oil improves outcomes in patients with parenteral nutrition-associated liver injury. Ann Surg 2009; 250:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/37/18007/abstract/12\">",
"      de Meijer VE, Gura KM, Le HD, et al. Fish oil-based lipid emulsions prevent and reverse parenteral nutrition-associated liver disease: the Boston experience. JPEN J Parenter Enteral Nutr 2009; 33:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/37/18007/abstract/13\">",
"      Burns DL, Gill BM. Reversal of parenteral nutrition-associated liver disease with a fish oil-based lipid emulsion (Omegaven) in an adult dependent on home parenteral nutrition. JPEN J Parenter Enteral Nutr 2013; 37:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/37/18007/abstract/14\">",
"      Nightingale JM, Lennard-Jones JE, Gertner DJ, et al. Colonic preservation reduces need for parenteral therapy, increases incidence of renal stones, but does not change high prevalence of gall stones in patients with a short bowel. Gut 1992; 33:1493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/37/18007/abstract/15\">",
"      Roslyn JJ, Pitt HA, Mann LL, et al. Gallbladder disease in patients on long-term parenteral nutrition. Gastroenterology 1983; 84:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/37/18007/abstract/16\">",
"      Dray X, Joly F, Reijasse D, et al. Incidence, risk factors, and complications of cholelithiasis in patients with home parenteral nutrition. J Am Coll Surg 2007; 204:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/37/18007/abstract/17\">",
"      Thompson JS. The role of prophylactic cholecystectomy in the short-bowel syndrome. Arch Surg 1996; 131:556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/37/18007/abstract/18\">",
"      Dibaise JK, Young RJ, Vanderhoof JA. Enteric microbial flora, bacterial overgrowth, and short-bowel syndrome. Clin Gastroenterol Hepatol 2006; 4:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/37/18007/abstract/19\">",
"      Ziegler TR, Cole CR. Small bowel bacterial overgrowth in adults: a potential contributor to intestinal failure. Curr Gastroenterol Rep 2007; 9:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/37/18007/abstract/20\">",
"      Salzedas-Netto AA, Silva RM, Martins JL, et al. Can bacterial translocation be a beneficial event? Transplant Proc 2006; 38:1836.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/37/18007/abstract/21\">",
"      Taylor SF, Sondheimer JM, Sokol RJ, et al. Noninfectious colitis associated with short gut syndrome in infants. J Pediatr 1991; 119:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/37/18007/abstract/22\">",
"      Vanderhoof JA, Young RJ, Murray N, Kaufman SS. Treatment strategies for small bowel bacterial overgrowth in short bowel syndrome. J Pediatr Gastroenterol Nutr 1998; 27:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/37/18007/abstract/23\">",
"      Modi BP, Javid PJ, Jaksic T, et al. First report of the international serial transverse enteroplasty data registry: indications, efficacy, and complications. J Am Coll Surg 2007; 204:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/37/18007/abstract/24\">",
"      Boncompain-G&eacute;rard M, Robert D, Fouque D, Hadj-A&iuml;ssa A. Renal function and urinary excretion of electrolytes in patients receiving cyclic parenteral nutrition. JPEN J Parenter Enteral Nutr 2000; 24:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/37/18007/abstract/25\">",
"      Ferrone M, Geraci M. A review of the relationship between parenteral nutrition and metabolic bone disease. Nutr Clin Pract 2007; 22:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/37/18007/abstract/26\">",
"      Boul&eacute;treau PH, Bost M, Fontanges E, et al. Fluoride exposure and bone status in patients with chronic intestinal failure who are receiving home parenteral nutrition. Am J Clin Nutr 2006; 83:1429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/37/18007/abstract/27\">",
"      Haderslev KV, Jeppesen PB, Hartmann B, et al. Short-term administration of glucagon-like peptide-2. Effects on bone mineral density and markers of bone turnover in short-bowel patients with no colon. Scand J Gastroenterol 2002; 37:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/37/18007/abstract/28\">",
"      Lin LY, Lin HC, Lee PC, et al. Hyperglycemia correlates with outcomes in patients receiving total parenteral nutrition. Am J Med Sci 2007; 333:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/37/18007/abstract/29\">",
"      Senkal M, Geier B, Hannemann M, et al. Supplementation of omega-3 fatty acids in parenteral nutrition beneficially alters phospholipid fatty acid pattern. JPEN J Parenter Enteral Nutr 2007; 31:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/37/18007/abstract/30\">",
"      Joly F, Dray X, Corcos O, et al. Tube feeding improves intestinal absorption in short bowel syndrome patients. Gastroenterology 2009; 136:824.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/37/18007/abstract/31\">",
"      Obialo CI, Clayman RV, Matts JP, et al. Pathogenesis of nephrolithiasis post-partial ileal bypass surgery: case-control study. The POSCH Group. Kidney Int 1991; 39:1249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/37/18007/abstract/32\">",
"      Nightingale JM. Hepatobiliary, renal and bone complications of intestinal failure. Best Pract Res Clin Gastroenterol 2003; 17:907.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/37/18007/abstract/33\">",
"      Halperin ML, Kamel KS. D-lactic acidosis: turning sugar into acids in the gastrointestinal tract. Kidney Int 1996; 49:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/37/18007/abstract/34\">",
"      Petersen C. D-lactic acidosis. Nutr Clin Pract 2005; 20:634.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/37/18007/abstract/35\">",
"      Coronado BE, Opal SM, Yoburn DC. Antibiotic-induced D-lactic acidosis. Ann Intern Med 1995; 122:839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/37/18007/abstract/36\">",
"      Messing B, Crenn P, Beau P, et al. Long-term survival and parenteral nutrition dependence in adult patients with the short bowel syndrome. Gastroenterology 1999; 117:1043.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/37/18007/abstract/37\">",
"      Vantini I, Benini L, Bonfante F, et al. Survival rate and prognostic factors in patients with intestinal failure. Dig Liver Dis 2004; 36:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/37/18007/abstract/38\">",
"      Lloyd DA, Vega R, Bassett P, et al. Survival and dependence on home parenteral nutrition: experience over a 25-year period in a UK referral centre. Aliment Pharmacol Ther 2006; 24:1231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/37/18007/abstract/39\">",
"      Vianna RM, Mangus RS. Present prospects and future perspectives of intestinal and multivisceral transplantation. Curr Opin Clin Nutr Metab Care 2009; 12:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/37/18007/abstract/40\">",
"      DeLegge M, Alsolaiman MM, Barbour E, et al. Short bowel syndrome: parenteral nutrition versus intestinal transplantation. Where are we today? Dig Dis Sci 2007; 52:876.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4775 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-190.111.122.2-510B38B3F6-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_37_18007=[""].join("\n");
var outline_f17_37_18007=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H13\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      HEPATOBILIARY DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Liver disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Prevention",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Gallstones",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      BACTERIAL OVERGROWTH",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      NUTRIENT ABNORMALITIES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      HYPEROXALURIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      D-LACTIC ACIDOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/4775\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/4775|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?40/43/41661\" title=\"table 1\">",
"      Oxalate content food AGA",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/18/18723?source=related_link\">",
"      D-Lactic acidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/6/44136?source=related_link\">",
"      Management of the short bowel syndrome in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/29/1497?source=related_link\">",
"      Overview of intestinal and multivisceral transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/18/18730?source=related_link\">",
"      Parenteral nutrition-associated liver disease in infants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/56/30601?source=related_link\">",
"      Pathophysiology of the short bowel syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/2/38953?source=related_link\">",
"      Prevention of recurrent calcium stones in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/53/33626?source=related_link\">",
"      Risk factors for calcium stones in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/50/28454?source=related_link\">",
"      Treatment of small intestinal bacterial overgrowth",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/32/43526?source=related_link\">",
"      Ursodeoxycholic acid in the treatment of primary biliary cirrhosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_37_18008="TDE pericarditis restrictive CM";
var content_f17_37_18008=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F64453&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F64453&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 520px\">",
"   <div class=\"ttl\">",
"    Doppler M-mode distinguishes between restrictive cardiomyopathy and constrictive pericarditis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 500px; height: 357px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Color Doppler M-mode echocardiographic&nbsp;imaging of the left ventricular posterior wall is seen in row 1, the calculated Doppler myocardial velocity gradient (MVG) is in row 2, and the corresponding transmitral pulsed-wave Doppler blood flow is seen in row 3. Panel A is from a patient with a restrictive cardiomyopathy (RCM), panel B is from a patient with constrictive pericarditis (CP) who has marked respiratory variation of blood flow (&gt;25 percent E-wave reduction in inspiration) and panel C is from a patient with constrictive pericarditis and absent respiratory variation (nondiagnostic E-wave reduction in inspiration). Arrows seen in row 2 indicate peak values of the MVG in the predetermined phases of the cardiac cycle. The rapid ventricular filling (RVF) MVG was 3 times higher in both CP patients (* in row 2, panels B and C) compared with RCM patient (panel A) and the isovolumic relaxation (IR) MVG was positive in RCM patient and negative in both CP patients (# in row 2, panels B and C).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from Palka, P, Lange, A, Donnelly, JE, Nihoyannopoulos, P. Circulation 2000; 102:655. Copyright &copy; 2000 Lippincott Williams &amp;Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_37_18008=[""].join("\n");
var outline_f17_37_18008=null;
var title_f17_37_18009="AIDS-related Kaposi sarcoma: Staging and treatment";
var content_f17_37_18009=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   AIDS-related Kaposi sarcoma: Staging and treatment",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/37/18009/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/37/18009/contributors\">",
"     Jerome E Groopman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/37/18009/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/37/18009/contributors\">",
"     Bruce J Dezube, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/37/18009/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/37/18009/contributors\">",
"     Michael E Ross, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?17/37/18009/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 8, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Kaposi's sarcoma (KS) is a low-grade vascular tumor associated with infection with human herpesvirus 8 (HHV-8), also known as the KS-associated herpesvirus (KSHV).",
"   </p>",
"   <p>",
"    AIDS-related KS has a variable clinical course, ranging from minimal disease presenting as an incidental finding to a rapidly progressing neoplasm that can result in significant morbidity and mortality, depending upon the specific sites of involvement [",
"    <a class=\"abstract\" href=\"UTD.htm?17/37/18009/abstract/1\">",
"     1",
"    </a>",
"    ]. In addition to physical symptoms due to tumors, the psychosocial burden associated with KS may be profound and includes emotional distress, guilt, and anger [",
"    <a class=\"abstract\" href=\"UTD.htm?17/37/18009/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The staging and treatment of AIDS-related Kaposi sarcoma are discussed here. The clinical manifestations and diagnosis of this disorder are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/52/12103?source=see_link\">",
"     \"AIDS-related Kaposi sarcoma: Clinical manifestations and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H432035701\">",
"    <span class=\"h1\">",
"     STAGING AND EVALUATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H432035415\">",
"    <span class=\"h2\">",
"     Staging system",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most commonly utilized staging system for AIDS-related KS was developed by the AIDS Clinical Trial Group (ACTG) of the National Institute of Health [",
"    <a class=\"abstract\" href=\"UTD.htm?17/37/18009/abstract/3\">",
"     3",
"    </a>",
"    ]. This system divides patients into good or poor risk prognostic categories, taking into account both the KS and HIV infection.",
"   </p>",
"   <p>",
"    Patients are categorized according to three parameters (",
"    <a class=\"graphic graphic_table graphicRef54626 \" href=\"UTD.htm?1/54/1900\">",
"     table 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Extent of tumor (T): a favorable prognosis (T0) is associated with disease limited to the skin or with minimal involvement of the oral cavity. Those with associated lymphedema, more extensive oral cavity involvement, or other visceral disease are considered to have a poor prognosis (T1).",
"     </li>",
"     <li>",
"      Immune status (I): the degree of immunosuppression from the HIV infection is an important prognostic factor. Patients with a CD4 count greater than 200",
"      <span class=\"nowrap\">",
"       cells/microL",
"      </span>",
"      are considered to have a favorable prognosis (I0) while those with a lower CD4 count have classified as poor prognosis (I1).",
"     </li>",
"     <li>",
"      Severity of systemic illness (S): Features associated with a poor risk included the following (S1): a history of opportunistic infection, thrush, B symptoms (fever, night sweats, significant weight loss, diarrhea for more than two weeks). Patients without any of these factors have a more favorable prognosis (S0).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The overall patient assessment requires that good-risk patients have a favorable prognosis according to all three parameters. This was illustrated by an analysis of 144 patients with KS prospectively included in the Swiss HIV Cohort Study [",
"    <a class=\"abstract\" href=\"UTD.htm?17/37/18009/abstract/4\">",
"     4",
"    </a>",
"    ]. On multivariate analysis, factors significantly associated with death or a need for chemotherapy included tumor stage T1 rather than T0, a CD4 count &lt;200",
"    <span class=\"nowrap\">",
"     cells/microL,",
"    </span>",
"    or a positive test for HHV-8 DNA (hazard ratios 5.2, 2.3, and 2.1, respectively).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Initial evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial evaluation of a patient with KS consists of a thorough physical examination with special attention paid to those areas typically affected by the disease, such as the lower extremities, face, oral mucosa, genitalia, gastrointestinal tract, and lungs.",
"   </p>",
"   <p>",
"    Evaluation for visceral involvement is guided by symptomatology and basic laboratory testing.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Testing the stool for occult blood is the simplest way to screen for gastrointestinal involvement. Endoscopy is usually reserved for patients who test positive for occult blood or have gastrointestinal symptoms.",
"     </li>",
"     <li>",
"      Chest x-ray is useful to screen for pulmonary lesions. Bronchoscopy should be reserved for those with an abnormal radiograph and persistent respiratory symptoms in the absence of another cause.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    CT scanning of the chest, abdomen, and pelvis is typically not necessary.",
"   </p>",
"   <p>",
"    The CD4 cell count and HIV viral load are important for staging and prognosis, and thus may be useful in making treatment decisions. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/52/21320?source=see_link\">",
"     \"Techniques and interpretation of measurement of the CD4 cell count in HIV-infected patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/44/39623?source=see_link\">",
"     \"Techniques and interpretation of HIV-1 RNA quantitation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major goals of treatment are symptom palliation, prevention of disease progression, and shrinkage of tumor to alleviate edema, organ compromise, and psychological stress [",
"    <a class=\"abstract\" href=\"UTD.htm?17/37/18009/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Systemic treatment with potent combination antiretroviral therapy (ART) is recommended for virtually all patients with AIDS-related KS [",
"    <a class=\"abstract\" href=\"UTD.htm?17/37/18009/abstract/5-7\">",
"     5-7",
"    </a>",
"    ]. The need for treatment beyond ART and the choice among the various options depend upon the extent of disease, the rapidity of tumor growth, the HIV-1 viral load, the CD4 cell count, and the patient's overall medical condition [",
"    <a class=\"abstract\" href=\"UTD.htm?17/37/18009/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Locally directed therapy is often used to palliate symptoms caused by a specific tumor or to treat cosmetic disfigurement. Systemic therapy is used for more extensive disease but injury to an immune system that is already severely compromised should be avoided whenever possible.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Combined antiretroviral therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Combination ART is recommended for virtually all patients with AIDS-related KS, and may be the only therapy required in the absence of specific indications for chemotherapy. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Systemic chemotherapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The introduction of ART has been associated with a substantial decrease in both the incidence and severity of newly diagnosed KS in HIV infected patients. A French database study that included 54,999 patients with over 180,000 patient years of follow-up found that the incidence rate for new cases of KS fell from 32 per 1000 person-years in 1993-1994 to 3 per 1000 person-years after 1999 [",
"    <a class=\"abstract\" href=\"UTD.htm?17/37/18009/abstract/9\">",
"     9",
"    </a>",
"    ]. Furthermore, the incidence of visceral involvement at presentation fell from more than 50 percent to less than 30 percent. Similar dramatic decreases have been seen in other studies [",
"    <a class=\"abstract\" href=\"UTD.htm?17/37/18009/abstract/10,11\">",
"     10,11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Observational studies indicate that the natural history of AIDS-related KS has changed since the introduction of ART in addition to a decrease in the KS incidence [",
"    <a class=\"abstract\" href=\"UTD.htm?17/37/18009/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. A retrospective study that analyzed KS cases from a database of 4439 persons with HIV infection both before ART (1990 to 1996) and after ART (1997 to 2002) found that the mean CD4 count and the mean HIV RNA levels were similar in the 366 patients from the pre-ART era and in the 40 patients in the post-ART era [",
"    <a class=\"abstract\" href=\"UTD.htm?17/37/18009/abstract/13\">",
"     13",
"    </a>",
"    ]. However, the overall risk of dying was significantly lower in the post-ART era (hazard ratio, 0.24).",
"   </p>",
"   <p>",
"    Immune reconstitution due to control of the HIV infection is the most likely explanation for this altered prognosis rather than a direct effect on tumor. Although HIV protease inhibitors have antiangiogenic properties and block the development and progression of KS-like lesions in nude mice [",
"    <a class=\"abstract\" href=\"UTD.htm?17/37/18009/abstract/14\">",
"     14",
"    </a>",
"    ], there was no difference in the likelihood of clinical response associated with the use of these agents [",
"    <a class=\"abstract\" href=\"UTD.htm?17/37/18009/abstract/12,15\">",
"     12,15",
"    </a>",
"    ]. Furthermore, the decreased incidence of KS has been observed with ART regimens that do not contain protease inhibitors [",
"    <a class=\"abstract\" href=\"UTD.htm?17/37/18009/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/24/36234?source=see_link\">",
"     \"Selecting antiretroviral regimens for the treatment naive HIV-infected patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although treatment with ART causes increases in CD4 counts above the levels typically associated with increased susceptibility to infection, some patients develop HIV-related KS despite apparent correction of their immunodeficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?17/37/18009/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Immune reconstitution inflammatory syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;The term \"immune reconstitution inflammatory syndrome\" (IRIS) is used to describe a collection of host responses that can occur following the initiation of ART. In addition to worsening of symptoms from preexisting infections with IRIS, the initiation of ART has been associated with progression of KS within three to six weeks after starting antiretroviral therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?17/37/18009/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/35/23098?source=see_link\">",
"     \"Immune reconstitution inflammatory syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The relationship between IRIS and KS is illustrated by two reports:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one series of 150 therapy-naive patients who presented with KS, 10 (7 percent) developed progressive KS when ART was initiated [",
"      <a class=\"abstract\" href=\"UTD.htm?17/37/18009/abstract/17\">",
"       17",
"      </a>",
"      ]. The risk of IRIS appeared to be increased in those with a higher CD4 count or KS-associated edema. Despite the progression of KS, continuation of ART was possible in these patients.",
"     </li>",
"     <li>",
"      In another series of nine cases from a single institution, the progression of KS occurred at a mean of five weeks after initiation of ART and was associated with a rising CD4 count and a decreasing viral load [",
"      <a class=\"abstract\" href=\"UTD.htm?17/37/18009/abstract/18\">",
"       18",
"      </a>",
"      ]. In all patients in whom systemic chemotherapy was used, tumor regression was observed, and discontinuation of ART was not required.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Local symptomatic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Local treatment modalities are useful for cosmesis or the management of symptomatic bulky KS lesions, but they do not prevent the development of new lesions in untreated areas.",
"   </p>",
"   <p>",
"    The most widely used local treatment approaches include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Intralesional chemotherapy &mdash; Intralesional chemotherapy can induce regression of injected tumors and is preferred for small lesions.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/3/4152?source=see_link\">",
"       Vinblastine",
"      </a>",
"      is the most widely used agent. It can be injected directly into a KS lesion as a 0.2 to 0.3",
"      <span class=\"nowrap\">",
"       mg/mL",
"      </span>",
"      solution with a volume of 0.1 mL per 0.5 cm",
"      <sup>",
"       2",
"      </sup>",
"      of lesion. Multiple injections may be necessary for larger lesions. A second series of injections is often necessary three to four weeks later. Treated lesions will fade and regress although typically not resolve completely [",
"      <a class=\"abstract\" href=\"UTD.htm?17/37/18009/abstract/19-21\">",
"       19-21",
"      </a>",
"      ]. In one series of 42 patients with oral KS, for example, 74 percent showed more than a 50 percent reduction in lesions; palliation was achieved for a mean of 4.3 months [",
"      <a class=\"abstract\" href=\"UTD.htm?17/37/18009/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Radiation therapy &mdash; The primary role of radiation therapy is to treat symptomatic disease that is too extensive to be treated with intralesional chemotherapy, but is not extensive enough to require systemic therapy. Although discomfort from radiotherapy is frequent, it usually resolves within two weeks of treatment. Radiation therapy does not have a role in patients with extensive KS, as was illustrated by a randomized trial from Zimbabwe [",
"      <a class=\"abstract\" href=\"UTD.htm?17/37/18009/abstract/22\">",
"       22",
"      </a>",
"      ]. In this trial, radiation therapy did not improve either quality of life or survival compared to supportive care alone in 495 patients who were not treated with antiretroviral drugs.",
"     </li>",
"     <li>",
"      Topical",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/45/25299?source=see_link\">",
"       alitretinoin",
"      </a>",
"      &mdash; Alitretinoin (9-cis retinoic acid) is available as a topical gel that the patient can apply to treat cutaneous KS lesions. This agent is rarely used, since the topical gel can cause inflammation and lead to pigmentation changes in dark-skinned patients. In two phase III studies involving 402 patients, alitretinoin was associated with a shorter time to response, a longer duration of response, and a longer time to disease progression compared to a placebo vehicle gel [",
"      <a class=\"abstract\" href=\"UTD.htm?17/37/18009/abstract/23,24\">",
"       23,24",
"      </a>",
"      ]. In these trials, responses were seen in 35 and 37 percent of patients after 12 weeks of treatment, compared to 7 and 18 percent with placebo. Responses were seen in patients with a wide range of baseline CD4+ lymphocyte counts.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Systemic chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Systemic chemotherapy is generally used for patients with more advanced KS or when there is evidence of rapid disease progression [",
"    <a class=\"abstract\" href=\"UTD.htm?17/37/18009/abstract/6\">",
"     6",
"    </a>",
"    ]. When chemotherapy is indicated, treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/13/10458?source=see_link\">",
"     pegylated liposomal doxorubicin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/53/9046?source=see_link\">",
"     liposomal daunorubicin",
"    </a>",
"    is generally recommended as the first-line treatment for KS [",
"    <a class=\"abstract\" href=\"UTD.htm?17/37/18009/abstract/6\">",
"     6",
"    </a>",
"    ]. Other agents that have been used include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/3/4152?source=see_link\">",
"     vinblastine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/29/1498?source=see_link\">",
"     vincristine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?17/37/18009/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Generally accepted indications for adding systemic chemotherapy to ART include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Widespread skin involvement (eg, more than 25 lesions)",
"     </li>",
"     <li>",
"      Extensive cutaneous KS that is unresponsive to local treatment",
"     </li>",
"     <li>",
"      Extensive edema",
"     </li>",
"     <li>",
"      Symptomatic visceral involvement",
"     </li>",
"     <li>",
"      Immune reconstitution inflammatory syndrome (IRIS) (see",
"      <a class=\"local\" href=\"#H15\">",
"       'Immune reconstitution inflammatory syndrome'",
"      </a>",
"      above)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Two small randomized trials have looked at the role of chemotherapy plus ART versus ART alone.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one trial, 112 patients who had not received prior ART or chemotherapy for KS were randomly assigned to ART (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/45/43734?source=see_link\">",
"       stavudine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"       lamivudine",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/12/18633?source=see_link\">",
"       nevirapine",
"      </a>",
"      ) with or without combination chemotherapy (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"       bleomycin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/29/1498?source=see_link\">",
"       vincristine",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?17/37/18009/abstract/26\">",
"       26",
"      </a>",
"      ]. The trial was limited to patients without symptomatic visceral disease or fungating lesions requiring urgent therapy. The overall was response of KS was significantly better with patients given chemotherapy plus ART (66 versus 39 percent). However, overall survival was 77 percent for the entire study population and there was no significant difference between the study arms.",
"     </li>",
"     <li>",
"      In another trial, 28 patients with moderate or advanced KS who were initiating a new ART regimen were randomly assigned to ART plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/13/10458?source=see_link\">",
"       liposomal doxorubicin",
"      </a>",
"      or ART alone [",
"      <a class=\"abstract\" href=\"UTD.htm?17/37/18009/abstract/27\">",
"       27",
"      </a>",
"      ]. Among those receiving chemotherapy with ART, 10 of 13 (76 percent) responded, compared to 3 of 15 (20 percent) with ART alone.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Liposomal anthracyclines",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/13/10458?source=see_link\">",
"     pegylated liposomal doxorubicin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/53/9046?source=see_link\">",
"     liposomal daunorubicin",
"    </a>",
"    is generally recommended as the first-line treatment for AIDS-related KS when systemic chemotherapy is indicated [",
"    <a class=\"abstract\" href=\"UTD.htm?17/37/18009/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pegylated anthracyclines have a longer plasma half-life than nonliposomal formulations. Liposomal formulations have less toxicity in nontarget organs than conventional anthracyclines and provide the theoretical advantage of higher tumor concentrations of drug. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/46/41706?source=see_link&amp;anchor=H20#H20\">",
"     \"Cardiotoxicity of anthracycline-like chemotherapy agents\", section on 'Liposome encapsulation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Liposomal anthracyclines can reliably shrink tumors, lessen edema, and cause the color of lesions to fade. Response rates range from 30 to 60 percent depending upon the definition of clinical response and the specifics of the various trials. In randomized multicenter trials, each of these agents was as effective as or superior to conventional combination chemotherapy (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/29/1498?source=see_link\">",
"     vincristine",
"    </a>",
"    with or without nonliposomal",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    ) in terms of response rates and had a better toxicity profile [",
"    <a class=\"abstract\" href=\"UTD.htm?17/37/18009/abstract/28-30\">",
"     28-30",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one trial, 258 patients were randomly assigned to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/13/10458?source=see_link\">",
"       pegylated liposomal doxorubicin",
"      </a>",
"      (20",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      every three weeks) or a combination regimen of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"       bleomycin",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/29/1498?source=see_link\">",
"       vincristine",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?17/37/18009/abstract/28\">",
"       28",
"      </a>",
"      ]. The response rate (virtually all responses were partial) was significantly higher with pegylated",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/13/10458?source=see_link\">",
"       liposomal doxorubicin",
"      </a>",
"      (46 versus 25 percent), which was also associated with less toxicity. Similar findings were noted in another trial of 241 patients (59 versus 23 percent response rate) [",
"      <a class=\"abstract\" href=\"UTD.htm?17/37/18009/abstract/29\">",
"       29",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A phase III trial comparing",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/53/9046?source=see_link\">",
"       liposomal daunorubicin",
"      </a>",
"      (40",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      every two weeks) to a combination regimen of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"       bleomycin",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/29/1498?source=see_link\">",
"       vincristine",
"      </a>",
"      found equivalent responses with the two regimens in terms of response rate (25 versus 28 percent, most of which were partial responses), median survival (369 versus 342 days), and median time to treatment failure (115 versus 99 days) [",
"      <a class=\"abstract\" href=\"UTD.htm?17/37/18009/abstract/30\">",
"       30",
"      </a>",
"      ]. There were fewer side effects with liposomal",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/15/43254?source=see_link\">",
"       daunorubicin",
"      </a>",
"      .",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a subsequent small, double-blind trial conducted between 1996 and 2000, 60 patients were randomly assigned to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/13/10458?source=see_link\">",
"     liposomal doxorubicin",
"    </a>",
"    , and 19 were assigned to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/53/9046?source=see_link\">",
"     liposomal daunorubicin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?17/37/18009/abstract/31\">",
"     31",
"    </a>",
"    ]. Both clinical benefit and tumor responses were more frequent with liposomal",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Side effects from these liposomal products are in general mild. In particular, alopecia and neuropathies are unusual with these preparations, in contrast to the side effect profile of conventional combination chemotherapy regimens. The diminished cardiotoxicity with liposomal anthracyclines permits higher cumulative doses of anthracycline to be administered, lengthening the duration over which these agents may be used [",
"    <a class=\"abstract\" href=\"UTD.htm?17/37/18009/abstract/30,32\">",
"     30,32",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/46/41706?source=see_link\">",
"     \"Cardiotoxicity of anthracycline-like chemotherapy agents\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The potential for prolonged control of KS was illustrated by a study of 98 patients treated with ART plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/13/10458?source=see_link\">",
"     pegylated liposomal doxorubicin",
"    </a>",
"    between 1997 and 2002 [",
"    <a class=\"abstract\" href=\"UTD.htm?17/37/18009/abstract/33\">",
"     33",
"    </a>",
"    ]. At a median follow-up of 29 months, 29 patients (30 percent) had died, including three with progressive KS. Among the 61 patients who had a complete or partial response of their KS, only eight (13 percent) relapsed after completing chemotherapy. The optimal duration of therapy with liposomal anthracyline is uncertain. A course of four to six cycles of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/13/10458?source=see_link\">",
"     liposomal doxorubicin",
"    </a>",
"    followed by a period of observation may be reasonable.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Taxanes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    is potentially more toxic than the liposomal anthracyclines, it has striking efficacy as a second-line treatment for KS [",
"    <a class=\"abstract\" href=\"UTD.htm?17/37/18009/abstract/34-38\">",
"     34-38",
"    </a>",
"    ], and may be an alternative for initial therapy of patients with advanced, symptomatic KS.",
"   </p>",
"   <p>",
"    The efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    was originally demonstrated in a phase II study in 28 evaluable patients, in which 20 (71 percent) had major responses to a regimen of 135",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    every three weeks. Responses were noted in all five patients with pulmonary KS and all four who had previously received anthracycline therapy. Toxicity included grade 4 thrombocytopenia in 6 of 29, and grade 4 neutropenia in 22 of 29 patients treated without hematopoietic growth factors.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"     Paclitaxel",
"    </a>",
"    (100",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    every two weeks) was compared with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/13/10458?source=see_link\">",
"     pegylated liposomal doxorubicin",
"    </a>",
"    (20",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    every three weeks) in a randomized trial conducted after the introduction of routine treatment with ART [",
"    <a class=\"abstract\" href=\"UTD.htm?17/37/18009/abstract/39\">",
"     39",
"    </a>",
"    ]. In that trial, 73 evaluable patients were enrolled between 1998 and 2002; the trial was terminated prematurely because of poor accrual. There were no statistically significant differences in response rate, progression-free survival, or overall survival. Treatment on both arms was associated with meaningful improvements in pain and swelling secondary to the tumor.",
"   </p>",
"   <p>",
"    The use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    regimens in KS patients is subject to two important interactions:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"       Paclitaxel",
"      </a>",
"      administration requires premedication with glucocorticoids. Because of the concern that steroids may further immunosuppress HIV-infected patients and exacerbate KS, the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      dose is typically reduced to 10 mg orally 12 and 6 hours prior to chemotherapy, instead of the usual 20 mg dose. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/57/43930?source=see_link&amp;anchor=H32#H32\">",
"       \"Infusion reactions to systemic chemotherapy\", section on 'Taxanes'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"       Paclitaxel",
"      </a>",
"      is metabolized through the cytochrome P450 enzymes, as are many of the antiretroviral drugs. Profound paclitaxel-related toxicity has been ascribed to an interaction between this drug and antiretroviral drugs in at least two patients [",
"      <a class=\"abstract\" href=\"UTD.htm?17/37/18009/abstract/40\">",
"       40",
"      </a>",
"      ]. However, others have failed to document alterations in paclitaxel elimination pharmacokinetics in one patient treated concurrently with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/36/25161?source=see_link\">",
"       indinavir",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/58/12202?source=see_link\">",
"       ritonavir",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?3/25/3482?source=see_link\">",
"       saquinavir",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/12/18633?source=see_link\">",
"       nevirapine",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?17/37/18009/abstract/41\">",
"       41",
"      </a>",
"      ]. Caution is urged when coadministering these agents. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/19/42294?source=see_link\">",
"       \"Systemic therapy for malignancy in patients on anti retroviral medications\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H432040144\">",
"    <span class=\"h2\">",
"     Steroids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Corticosteroid therapy has been associated with the induction of KS and with the exacerbation of preexisting KS in HIV-infected persons, as well as in non-AIDS patients receiving corticosteroids for organ transplantation, autoimmune disorders, or lymphoproliferative diseases [",
"    <a class=\"abstract\" href=\"UTD.htm?17/37/18009/abstract/42\">",
"     42",
"    </a>",
"    ]. &nbsp;The association of corticosteroids with KS is important because of the frequent use of these agents in HIV-infected patients with a variety of disorders including immune thrombocytopenic purpura and Pneumocystis jirovecii pneumonia.",
"   </p>",
"   <p>",
"    In patients being treated with steroids, KS lesions may regress upon reduction or withdrawal of steroids [",
"    <a class=\"abstract\" href=\"UTD.htm?17/37/18009/abstract/42,43\">",
"     42,43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Other agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of other agents have been studied in a more limited way in patients with AIDS-related KS, and these may have utility as second line therapy:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/59/953?source=see_link\">",
"       Vinorelbine",
"      </a>",
"      &ndash; Vinorelbine may be effective in the treatment of patients with AIDS-related KS who have failed other treatments, including other vinca alkaloids. In one series of 35 patients treated with vinorelbine (30",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      every two weeks), three (9 percent) had a complete clinical response, and 12 (34 percent) had a partial response, which lasted for a median of 151 days [",
"      <a class=\"abstract\" href=\"UTD.htm?17/37/18009/abstract/44\">",
"       44",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"       Etoposide",
"      </a>",
"      &ndash; Oral etoposide has been reported to have activity in AIDS-related KS when given either in fractionated doses (20",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      every eight hours for 7 of 21 days) [",
"      <a class=\"abstract\" href=\"UTD.htm?17/37/18009/abstract/45\">",
"       45",
"      </a>",
"      ] or as a once daily dose of 50 mg for 7 of every 21 days [",
"      <a class=\"abstract\" href=\"UTD.htm?17/37/18009/abstract/46\">",
"       46",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Interferon-alfa &ndash; Interferon-alfa (IFNa) is a biologic response modifier that produces clinically significant responses in approximately 20 to 40 percent of patients with AIDS-related KS, especially those with disease limited to the skin and relatively modest immunosuppression [",
"      <a class=\"abstract\" href=\"UTD.htm?17/37/18009/abstract/47,48\">",
"       47,48",
"      </a>",
"      ]. However, IFNa is rarely used because of the availability of other agents with a more favorable benefit-to-risk ratio.",
"      <br/>",
"      <br/>",
"      In a randomized trial, patients with AIDS-related KS were treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/28/24008?source=see_link\">",
"       zidovudine",
"      </a>",
"      and IFNa at a dose of either one or eight million units subcutaneously per day [",
"      <a class=\"abstract\" href=\"UTD.htm?17/37/18009/abstract/48\">",
"       48",
"      </a>",
"      ]. With the high-dose regimen, the response rate was much higher (31 versus 8 percent) and the median time to progression longer (18 versus 13 weeks). Responses at both doses were more likely in patients with CD4 counts above",
"      <span class=\"nowrap\">",
"       150/microL.",
"      </span>",
"      However, almost all patients in the high-dose arm required dose reduction for significant toxicity consisting of fever, chills, rigors, neutropenia, hepatotoxicity, and cognitive impairment.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Experimental approaches",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recent advances in the understanding of the pathogenesis of KS are uncovering potential targets for KS therapies [",
"    <a class=\"abstract\" href=\"UTD.htm?17/37/18009/abstract/49,50\">",
"     49,50",
"    </a>",
"    ]. Such targets include angiogenesis, sex hormones, vitamin D and its analogs, and cellular differentiation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/52/12103?source=see_link\">",
"     \"AIDS-related Kaposi sarcoma: Clinical manifestations and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"       Imatinib",
"      </a>",
"      &mdash; Imatinib is an orally active tyrosine kinase inhibitor that has demonstrated activity in AIDS-related cutaneous KS. In a pilot series, five of ten men with progressive disease despite chemotherapy",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      ART had an objective partial response to imatinib (300 mg twice daily) [",
"      <a class=\"abstract\" href=\"UTD.htm?17/37/18009/abstract/51\">",
"       51",
"      </a>",
"      ]. A larger trial has been completed by the",
"      <span class=\"nowrap\">",
"       NIH/National",
"      </span>",
"      Cancer Institute; final results are not yet available. Activation of the platelet-derived growth factor and c-kit receptors (both receptor tyrosine kinases) are important in the growth of KS lesions and imatinib inhibits both of these receptors.",
"     </li>",
"     <li>",
"      Inhibitors of mTOR pathway &mdash; Rapamycin and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/1/14360?source=see_link\">",
"       temsirolimus",
"      </a>",
"      are inhibitors of the mTOR pathway and appear to have activity in patients with KS. The demonstration of patients who had regression of their transplant-related KS when treated with rapamycin indicates that the",
"      <span class=\"nowrap\">",
"       PI3K/AKT/mTOR",
"      </span>",
"      pathway may be important in the pathogenesis of KS [",
"      <a class=\"abstract\" href=\"UTD.htm?17/37/18009/abstract/52\">",
"       52",
"      </a>",
"      ]. In another study, seven patients with HIV-related KS were treated with a combination of rapamycin plus antiretroviral therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?17/37/18009/abstract/53\">",
"       53",
"      </a>",
"      ]. Three patients, all on protease inhibitor containing regimens, had a partial response of their KS to treatment.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/20/2377?source=see_link\">",
"       Bevacizumab",
"      </a>",
"      &mdash; Bevacizumab is a monoclonal antibody directed against vascular endothelial growth factor, which contributes to the pathogenesis of KS. In a phase II study, treatment of 17 patients with HIV associated KS using bevacizumab resulted in objective responses (complete or partial) in five cases and stable disease in nine additional cases [",
"      <a class=\"abstract\" href=\"UTD.htm?17/37/18009/abstract/54\">",
"       54",
"      </a>",
"      ]. Additional studies will be required to determine the role of bevacizumab in these patients.",
"     </li>",
"     <li>",
"      Vitamin D and its analogs &mdash; Primary KS tumors and cell lines derived from KS lesions express high levels of the vitamin D receptor. In one report, treatment with 1, 25 dihydroxyvitamin D3 inhibited the growth of KS cells in vitro and in xenograft models [",
"      <a class=\"abstract\" href=\"UTD.htm?17/37/18009/abstract/55\">",
"       55",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Miscellaneous agents &mdash; A number of other agents have shown at least some evidence of activity in early studies in patients with AIDS-related KS. These include the angiogenesis inhibitors fumagillin [",
"      <a class=\"abstract\" href=\"UTD.htm?17/37/18009/abstract/56\">",
"       56",
"      </a>",
"      ] and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"       thalidomide",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?17/37/18009/abstract/57\">",
"       57",
"      </a>",
"      ], the differentiation-inducing agent 9-cis retinoic acid [",
"      <a class=\"abstract\" href=\"UTD.htm?17/37/18009/abstract/58\">",
"       58",
"      </a>",
"      ], the matrix metalloproteinase inhibitor COL-3 [",
"      <a class=\"abstract\" href=\"UTD.htm?17/37/18009/abstract/59\">",
"       59",
"      </a>",
"      ], interleukin-12 [",
"      <a class=\"abstract\" href=\"UTD.htm?17/37/18009/abstract/60,61\">",
"       60,61",
"      </a>",
"      ], and intralesional injection of human chorionic gonadotropin [",
"      <a class=\"abstract\" href=\"UTD.htm?17/37/18009/abstract/62,63\">",
"       62,63",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/60/1994?source=see_link\">",
"       \"Overview of angiogenesis inhibitors\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Anti-HHV-8 therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Identification of HHV-8 as the etiologic agent of KS provides another potential target for treatment. However, there are no specific anti-HHV-8 therapies available.",
"   </p>",
"   <p>",
"    Case-control studies of historical cohorts of HIV-seropositive subjects suggest that there is a lower incidence of KS in patients treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"     ganciclovir",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/56/29575?source=see_link\">",
"     foscarnet",
"    </a>",
"    , but not",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?17/37/18009/abstract/64,65\">",
"     64,65",
"    </a>",
"    ]. Indirect evidence for the efficacy of ganciclovir also comes from a randomized trial in which 377 HIV-seropositive patients with cytomegalovirus retinitis were assigned to receive a ganciclovir intraocular implant plus oral ganciclovir, a ganciclovir implant plus oral placebo, or intravenous ganciclovir alone [",
"    <a class=\"abstract\" href=\"UTD.htm?17/37/18009/abstract/66\">",
"     66",
"    </a>",
"    ]. Treatment with oral or intravenous ganciclovir reduced the risk of KS by 75 and 93 percent, respectively, compared with placebo.",
"   </p>",
"   <p>",
"    New agents might inhibit the specific protein products of the virus that contribute to KS spindle cell growth as well as block the effects of the switched-on chemokine receptor. As this work progresses, the primary focus will be to sustain a high level of cellular immunity with antiretroviral therapy so that host defenses can provide the needed surveillance to suppress the neoplasm.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"./kaposis-sarcoma-the-basics?source=see_link\">",
"       \"Patient information: Kaposi&rsquo;s sarcoma (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For HIV-positive patients who develop either limited or advanced Kaposi sarcoma (KS), we recommend that treatment include highly active antiretroviral therapy (ART) (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). For some patients, ART maybe sufficient to induce regression of the KS. Others will require ART plus local or systemic chemotherapy. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Combined antiretroviral therapy'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/24/36234?source=see_link\">",
"       \"Selecting antiretroviral regimens for the treatment naive HIV-infected patient\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients who have limited disease causing symptoms or cosmetic disfigurement, we suggest local treatment rather than systemic chemotherapy in addition to ART (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). For patients with small lesions, we suggest intralesional chemotherapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ); for those with larger lesions that cannot be managed with intralesional chemotherapy, we suggest radiation therapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Local symptomatic therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Indications for systemic chemotherapy include extensive cutaneous disease, symptomatic visceral involvement, and cutaneous KS that is unresponsive to local therapy. Chemotherapy is also indicated for patients with the immune reconstitution inflammatory syndrome (ie, progressive KS within weeks after initiation of ART). (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Immune reconstitution inflammatory syndrome'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For initial systemic chemotherapy in patients with advanced KS, we recommend a liposomal anthracycline (either",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/13/10458?source=see_link\">",
"       pegylated liposomal doxorubicin",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/53/9046?source=see_link\">",
"       liposomal daunorubicin",
"      </a>",
"      ), rather than a combination of older agents or a taxane (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Systemic chemotherapy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H18\">",
"       'Liposomal anthracyclines'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients who have progressed on a liposomal anthracycline, we suggest chemotherapy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"       paclitaxel",
"      </a>",
"      &nbsp;(",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Taxanes'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/37/18009/abstract/1\">",
"      Dezube BJ. Clinical presentation and natural history of AIDS--related Kaposi's sarcoma. Hematol Oncol Clin North Am 1996; 10:1023.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/37/18009/abstract/2\">",
"      Holland JC, Tross S. Psychosocial considerations in the therapy of epidemic Kaposi's sarcoma. Semin Oncol 1987; 14:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/37/18009/abstract/3\">",
"      Krown SE, Metroka C, Wernz JC. Kaposi's sarcoma in the acquired immune deficiency syndrome: a proposal for uniform evaluation, response, and staging criteria. AIDS Clinical Trials Group Oncology Committee. J Clin Oncol 1989; 7:1201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/37/18009/abstract/4\">",
"      El Amari EB, Toutous-Trellu L, Gayet-Ageron A, et al. Predicting the evolution of Kaposi sarcoma, in the highly active antiretroviral therapy era. AIDS 2008; 22:1019.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/37/18009/abstract/5\">",
"      Dezube BJ, Pantanowitz L, Aboulafia DM. Management of AIDS-related Kaposi sarcoma: advances in target discovery and treatment. AIDS Read 2004; 14:236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/37/18009/abstract/6\">",
"      Bower M, Collins S, Cottrill C, et al. British HIV Association guidelines for HIV-associated malignancies 2008. HIV Med 2008; 9:336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/37/18009/abstract/7\">",
"      Krown SE. Highly active antiretroviral therapy in AIDS-associated Kaposi's sarcoma: implications for the design of therapeutic trials in patients with advanced, symptomatic Kaposi's sarcoma. J Clin Oncol 2004; 22:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/37/18009/abstract/8\">",
"      Stebbing J, Sanitt A, Nelson M, et al. A prognostic index for AIDS-associated Kaposi's sarcoma in the era of highly active antiretroviral therapy. Lancet 2006; 367:1495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/37/18009/abstract/9\">",
"      Grabar S, Abraham B, Mahamat A, et al. Differential impact of combination antiretroviral therapy in preventing Kaposi's sarcoma with and without visceral involvement. J Clin Oncol 2006; 24:3408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/37/18009/abstract/10\">",
"      Franceschi S, Maso LD, Rickenbach M, et al. Kaposi sarcoma incidence in the Swiss HIV Cohort Study before and after highly active antiretroviral therapy. Br J Cancer 2008; 99:800.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/37/18009/abstract/11\">",
"      Mocroft A, Kirk O, Clumeck N, et al. The changing pattern of Kaposi sarcoma in patients with HIV, 1994-2003: the EuroSIDA Study. Cancer 2004; 100:2644.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/37/18009/abstract/12\">",
"      Gill J, Bourboulia D, Wilkinson J, et al. Prospective study of the effects of antiretroviral therapy on Kaposi sarcoma--associated herpesvirus infection in patients with and without Kaposi sarcoma. J Acquir Immune Defic Syndr 2002; 31:384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/37/18009/abstract/13\">",
"      Gallafent JH, Buskin SE, De Turk PB, Aboulafia DM. Profile of patients with Kaposi's sarcoma in the era of highly active antiretroviral therapy. J Clin Oncol 2005; 23:1253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/37/18009/abstract/14\">",
"      Sgadari C, Barillari G, Toschi E, et al. HIV protease inhibitors are potent anti-angiogenic molecules and promote regression of Kaposi sarcoma. Nat Med 2002; 8:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/37/18009/abstract/15\">",
"      Martinez V, Caumes E, Gambotti L, et al. Remission from Kaposi's sarcoma on HAART is associated with suppression of HIV replication and is independent of protease inhibitor therapy. Br J Cancer 2006; 94:1000.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/37/18009/abstract/16\">",
"      Krown SE, Lee JY, Dittmer DP, AIDS Malignancy Consortium. More on HIV-associated Kaposi's sarcoma. N Engl J Med 2008; 358:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/37/18009/abstract/17\">",
"      Bower M, Nelson M, Young AM, et al. Immune reconstitution inflammatory syndrome associated with Kaposi's sarcoma. J Clin Oncol 2005; 23:5224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/37/18009/abstract/18\">",
"      Leidner RS, Aboulafia DM. Recrudescent Kaposi's sarcoma after initiation of HAART: a manifestation of immune reconstitution syndrome. AIDS Patient Care STDS 2005; 19:635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/37/18009/abstract/19\">",
"      Epstein JB. Treatment of oral Kaposi sarcoma with intralesional vinblastine. Cancer 1993; 71:1722.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/37/18009/abstract/20\">",
"      McCormick SU. Intralesional vinblastine injections for the treatment of oral Kaposi's sarcoma: report of 10 patients with 2-year follow-up. J Oral Maxillofac Surg 1996; 54:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/37/18009/abstract/21\">",
"      Ram&iacute;rez-Amador V, Esquivel-Pedraza L, Lozada-Nur F, et al. Intralesional vinblastine vs. 3% sodium tetradecyl sulfate for the treatment of oral Kaposi's sarcoma. A double blind, randomized clinical trial. Oral Oncol 2002; 38:460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/37/18009/abstract/22\">",
"      Olweny CL, Borok M, Gudza I, et al. Treatment of AIDS-associated Kaposi's sarcoma in Zimbabwe: results of a randomized quality of life focused clinical trial. Int J Cancer 2005; 113:632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/37/18009/abstract/23\">",
"      Walmsley S, Northfelt DW, Melosky B, et al. Treatment of AIDS-related cutaneous Kaposi's sarcoma with topical alitretinoin (9-cis-retinoic acid) gel. Panretin Gel North American Study Group. J Acquir Immune Defic Syndr 1999; 22:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/37/18009/abstract/24\">",
"      Bodsworth NJ, Bloch M, Bower M, et al. Phase III vehicle-controlled, multi-centered study of topical alitretinoin gel 0.1% in cutaneous AIDS-related Kaposi's sarcoma. Am J Clin Dermatol 2001; 2:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/37/18009/abstract/25\">",
"      Lee FC, Mitsuyasu RT. Chemotherapy of AIDS--related Kaposi's sarcoma. Hematol Oncol Clin North Am 1996; 10:1051.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/37/18009/abstract/26\">",
"      Mosam A, Shaik F, Uldrick TS, et al. A randomized controlled trial of highly active antiretroviral therapy versus highly active antiretroviral therapy and chemotherapy in therapy-naive patients with HIV-associated Kaposi sarcoma in South Africa. J Acquir Immune Defic Syndr 2012; 60:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/37/18009/abstract/27\">",
"      Martin-Carbonero L, Barrios A, Saballs P, et al. Pegylated liposomal doxorubicin plus highly active antiretroviral therapy versus highly active antiretroviral therapy alone in HIV patients with Kaposi's sarcoma. AIDS 2004; 18:1737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/37/18009/abstract/28\">",
"      Northfelt DW, Dezube BJ, Thommes JA, et al. Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized phase III clinical trial. J Clin Oncol 1998; 16:2445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/37/18009/abstract/29\">",
"      Stewart S, Jablonowski H, Goebel FD, et al. Randomized comparative trial of pegylated liposomal doxorubicin versus bleomycin and vincristine in the treatment of AIDS-related Kaposi's sarcoma. International Pegylated Liposomal Doxorubicin Study Group. J Clin Oncol 1998; 16:683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/37/18009/abstract/30\">",
"      Gill PS, Wernz J, Scadden DT, et al. Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi's sarcoma. J Clin Oncol 1996; 14:2353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/37/18009/abstract/31\">",
"      Cooley T, Henry D, Tonda M, et al. A randomized, double-blind study of pegylated liposomal doxorubicin for the treatment of AIDS-related Kaposi's sarcoma. Oncologist 2007; 12:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/37/18009/abstract/32\">",
"      Young AM, Dhillon T, Bower M. Cardiotoxicity after liposomal anthracyclines. Lancet Oncol 2004; 5:654.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/37/18009/abstract/33\">",
"      Mart&iacute;n-Carbonero L, Palacios R, Valencia E, et al. Long-term prognosis of HIV-infected patients with Kaposi sarcoma treated with pegylated liposomal doxorubicin. Clin Infect Dis 2008; 47:410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/37/18009/abstract/34\">",
"      Welles L, Saville MW, Lietzau J, et al. Phase II trial with dose titration of paclitaxel for the therapy of human immunodeficiency virus-associated Kaposi's sarcoma. J Clin Oncol 1998; 16:1112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/37/18009/abstract/35\">",
"      Gill PS, Tulpule A, Espina BM, et al. Paclitaxel is safe and effective in the treatment of advanced AIDS-related Kaposi's sarcoma. J Clin Oncol 1999; 17:1876.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/37/18009/abstract/36\">",
"      Tulpule A, Groopman J, Saville MW, et al. Multicenter trial of low-dose paclitaxel in patients with advanced AIDS-related Kaposi sarcoma. Cancer 2002; 95:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/37/18009/abstract/37\">",
"      Lee, FC, Thornton, K, Williams, B. Low dose weekly paclitaxel is an effective first line treatment for patients with symptomatic AIDS-KS (abstract). Proc Am Soc Clin Oncol 2003; 22:825a.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/37/18009/abstract/38\">",
"      Lim ST, Tupule A, Espina BM, Levine AM. Weekly docetaxel is safe and effective in the treatment of advanced-stage acquired immunodeficiency syndrome-related Kaposi sarcoma. Cancer 2005; 103:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/37/18009/abstract/39\">",
"      Cianfrocca M, Lee S, Von Roenn J, et al. Randomized trial of paclitaxel versus pegylated liposomal doxorubicin for advanced human immunodeficiency virus-associated Kaposi sarcoma: evidence of symptom palliation from chemotherapy. Cancer 2010; 116:3969.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/37/18009/abstract/40\">",
"      Schwartz JD, Howard W, Scadden DT. Potential interaction of antiretroviral therapy with paclitaxel in patients with AIDS-related Kaposi's sarcoma. AIDS 1999; 13:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/37/18009/abstract/41\">",
"      Nannan Panday VR, Hoetelmans RM, van Heeswijk RP, et al. Paclitaxel in the treatment of human immunodeficiency virus 1-associated Kaposi's sarcoma--drug-drug interactions with protease inhibitors and a nonnucleoside reverse transcriptase inhibitor: a case report study. Cancer Chemother Pharmacol 1999; 43:516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/37/18009/abstract/42\">",
"      Trattner A, Hodak E, David M, Sandbank M. The appearance of Kaposi sarcoma during corticosteroid therapy. Cancer 1993; 72:1779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/37/18009/abstract/43\">",
"      Gill PS, Loureiro C, Bernstein-Singer M, et al. Clinical effect of glucocorticoids on Kaposi sarcoma related to the acquired immunodeficiency syndrome (AIDS). Ann Intern Med 1989; 110:937.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/37/18009/abstract/44\">",
"      Nasti G, Errante D, Talamini R, et al. Vinorelbine is an effective and safe drug for AIDS-related Kaposi's sarcoma: results of a phase II study. J Clin Oncol 2000; 18:1550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/37/18009/abstract/45\">",
"      Sprinz E, Caldas AP, Mans DR, et al. Fractionated doses of oral etoposide in the treatment of patients with aids-related kaposi sarcoma: a clinical and pharmacologic study to improve therapeutic index. Am J Clin Oncol 2001; 24:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/37/18009/abstract/46\">",
"      Evans SR, Krown SE, Testa MA, et al. Phase II evaluation of low-dose oral etoposide for the treatment of relapsed or progressive AIDS-related Kaposi's sarcoma: an AIDS Clinical Trials Group clinical study. J Clin Oncol 2002; 20:3236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/37/18009/abstract/47\">",
"      Krown SE, Li P, Von Roenn JH, et al. Efficacy of low-dose interferon with antiretroviral therapy in Kaposi's sarcoma: a randomized phase II AIDS clinical trials group study. J Interferon Cytokine Res 2002; 22:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/37/18009/abstract/48\">",
"      Shepherd FA, Beaulieu R, Gelmon K, et al. Prospective randomized trial of two dose levels of interferon alfa with zidovudine for the treatment of Kaposi's sarcoma associated with human immunodeficiency virus infection: a Canadian HIV Clinical Trials Network study. J Clin Oncol 1998; 16:1736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/37/18009/abstract/49\">",
"      Karp JE, Pluda JM, Yarchoan R. AIDS-related Kaposi's sarcoma. A template for the translation of molecular pathogenesis into targeted therapeutic approaches. Hematol Oncol Clin North Am 1996; 10:1031.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/37/18009/abstract/50\">",
"      McGarvey ME, Tulpule A, Cai J, et al. Emerging treatments for epidemic (AIDS-related) Kaposi's sarcoma. Curr Opin Oncol 1998; 10:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/37/18009/abstract/51\">",
"      Koon HB, Bubley GJ, Pantanowitz L, et al. Imatinib-induced regression of AIDS-related Kaposi's sarcoma. J Clin Oncol 2005; 23:982.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/37/18009/abstract/52\">",
"      Stallone G, Schena A, Infante B, et al. Sirolimus for Kaposi's sarcoma in renal-transplant recipients. N Engl J Med 2005; 352:1317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/37/18009/abstract/53\">",
"      Krown SE, Roy D, Lee JY, et al. Rapamycin with antiretroviral therapy in AIDS-associated Kaposi sarcoma: an AIDS Malignancy Consortium study. J Acquir Immune Defic Syndr 2012; 59:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/37/18009/abstract/54\">",
"      Uldrick TS, Wyvill KM, Kumar P, et al. Phase II study of bevacizumab in patients with HIV-associated Kaposi's sarcoma receiving antiretroviral therapy. J Clin Oncol 2012; 30:1476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/37/18009/abstract/55\">",
"      Masood R, Nagpal S, Zheng T, et al. Kaposi sarcoma is a therapeutic target for vitamin D(3) receptor agonist. Blood 2000; 96:3188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/37/18009/abstract/56\">",
"      Dezube BJ, Von Roenn JH, Holden-Wiltse J, et al. Fumagillin analog in the treatment of Kaposi's sarcoma: a phase I AIDS Clinical Trial Group study. AIDS Clinical Trial Group No. 215 Team. J Clin Oncol 1998; 16:1444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/37/18009/abstract/57\">",
"      Little RF, Wyvill KM, Pluda JM, et al. Activity of thalidomide in AIDS-related Kaposi's sarcoma. J Clin Oncol 2000; 18:2593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/37/18009/abstract/58\">",
"      Miles SA, Dezube BJ, Lee JY, et al. Antitumor activity of oral 9-cis-retinoic acid in HIV-associated Kaposi's sarcoma. AIDS 2002; 16:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/37/18009/abstract/59\">",
"      Dezube BJ, Krown SE, Lee JY, et al. Randomized phase II trial of matrix metalloproteinase inhibitor COL-3 in AIDS-related Kaposi's sarcoma: an AIDS Malignancy Consortium Study. J Clin Oncol 2006; 24:1389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/37/18009/abstract/60\">",
"      Little RF, Pluda JM, Wyvill KM, et al. Activity of subcutaneous interleukin-12 in AIDS-related Kaposi sarcoma. Blood 2006; 107:4650.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/37/18009/abstract/61\">",
"      Little RF, Aleman K, Kumar P, et al. Phase 2 study of pegylated liposomal doxorubicin in combination with interleukin-12 for AIDS-related Kaposi sarcoma. Blood 2007; 110:4165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/37/18009/abstract/62\">",
"      Gill PS, Lunardi-Ishkandar Y, Louie S, et al. The effects of preparations of human chorionic gonadotropin on AIDS-related Kaposi's sarcoma. N Engl J Med 1996; 335:1261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/37/18009/abstract/63\">",
"      Gill PS, McLaughlin T, Espina BM, et al. Phase I study of human chorionic gonadotropin given subcutaneously to patients with acquired immunodeficiency syndrome-related mucocutaneous Kaposi's sarcoma. J Natl Cancer Inst 1997; 89:1797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/37/18009/abstract/64\">",
"      Mocroft A, Youle M, Gazzard B, et al. Anti-herpesvirus treatment and risk of Kaposi's sarcoma in HIV infection. Royal Free/Chelsea and Westminster Hospitals Collaborative Group. AIDS 1996; 10:1101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/37/18009/abstract/65\">",
"      Glesby MJ, Hoover DR, Weng S, et al. Use of antiherpes drugs and the risk of Kaposi's sarcoma: data from the Multicenter AIDS Cohort Study. J Infect Dis 1996; 173:1477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/37/18009/abstract/66\">",
"      Martin DF, Kuppermann BD, Wolitz RA, et al. Oral ganciclovir for patients with cytomegalovirus retinitis treated with a ganciclovir implant. Roche Ganciclovir Study Group. N Engl J Med 1999; 340:1063.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8034 Version 15.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-41.196.66.12-E4B97AEF56-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_37_18009=[""].join("\n");
var outline_f17_37_18009=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H23\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H432035701\">",
"      STAGING AND EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H432035415\">",
"      Staging system",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Initial evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Combined antiretroviral therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Immune reconstitution inflammatory syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Local symptomatic therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Systemic chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Liposomal anthracyclines",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Taxanes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H432040144\">",
"      Steroids",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Other agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Experimental approaches",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Anti-HHV-8 therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/8034\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/8034|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?1/54/1900\" title=\"table 1\">",
"      Staging classification AIDS KS",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/52/12103?source=related_link\">",
"      AIDS-related Kaposi sarcoma: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/46/41706?source=related_link\">",
"      Cardiotoxicity of anthracycline-like chemotherapy agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/35/23098?source=related_link\">",
"      Immune reconstitution inflammatory syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/57/43930?source=related_link\">",
"      Infusion reactions to systemic chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/60/1994?source=related_link\">",
"      Overview of angiogenesis inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"./kaposis-sarcoma-the-basics?source=related_link\">",
"      Patient information: Kaposi&rsquo;s sarcoma (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/24/36234?source=related_link\">",
"      Selecting antiretroviral regimens for the treatment naive HIV-infected patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/19/42294?source=related_link\">",
"      Systemic therapy for malignancy in patients on anti retroviral medications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/44/39623?source=related_link\">",
"      Techniques and interpretation of HIV-1 RNA quantitation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/52/21320?source=related_link\">",
"      Techniques and interpretation of measurement of the CD4 cell count in HIV-infected patients",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_37_18010="Percutaneous angioplasty for the treatment of venous stenosis affecting hemodialysis access grafts";
var content_f17_37_18010=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Percutaneous angioplasty for the treatment of venous stenosis affecting hemodialysis access grafts",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/37/18010/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/37/18010/contributors\">",
"     Gerald A Beathard, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/37/18010/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/37/18010/contributors\">",
"     Steve J Schwab, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/37/18010/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/37/18010/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?17/37/18010/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 27, 2009.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dialysis facilities should have the capability and expertise to prospectively diagnose and, when indicated, treat venous stenosis associated with prosthetic bridge grafts (PBG) utilized for hemodialysis access. Different modalities",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    criteria have been promoted to screen for and diagnose angiographic and hemodynamically significant venous stenosis. The 2006 National Kidney Foundation-Dialysis Outcomes Quality Initiative",
"    <span class=\"nowrap\">",
"     (NKF/DOQI",
"    </span>",
"    or",
"    <span class=\"nowrap\">",
"     K/DOQI)",
"    </span>",
"    hemodialysis access working group recommend that a hemodynamically significant stenosis requiring intervention should display a &ge;50 percent stenosis (as determined radiographically) plus evidence of a clinical or physiologic abnormality (eg, elevated venous pressure or decreased blood flow) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/37/18010/abstract/1\">",
"     1",
"    </a>",
"    ]. The",
"    <span class=\"nowrap\">",
"     K/DOQI",
"    </span>",
"    clinical practice guidelines for vascular access, as well as other",
"    <span class=\"nowrap\">",
"     K/DOQI",
"    </span>",
"    guidelines, can be accessed through the National Kidney Foundation's web site at",
"    <a class=\"external\" href=\"file://www.kidney.org/professionals/kdoqi/guidelines.cfm\">",
"     www.kidney.org/professionals/kdoqi/guidelines.cfm",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Since the early reports of success, angioplasty has become the standard treatment for venous stenosis in both fistulae and grafts using techniques that have become relatively standardized [",
"    <a class=\"abstract\" href=\"UTD.htm?17/37/18010/abstract/2-5\">",
"     2-5",
"    </a>",
"    ]. This is in part due to an improvement in the ability to predict the presence of venous stenosis prospectively through access monitoring and surveillance. It is also due to the fact that the technique has been demonstrated to be safe, easily performed, and effective [",
"    <a class=\"abstract\" href=\"UTD.htm?17/37/18010/abstract/2-8\">",
"     2-8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A review of percutaneous angioplasty for the treatment of venous stenosis affecting hemodialysis access grafts is discussed here. Issues surrounding the treatment of stenosis of AV fistulas, as well as the monitoring and diagnosis of stenosis of chronic hemodialysis access are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/38/615?source=see_link\">",
"     \"Monitoring and surveillance of hemodialysis arteriovenous grafts to prevent thrombosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/50/27429?source=see_link\">",
"     \"Monitoring and surveillance of hemodialysis arteriovenous fistulas to prevent thrombosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/21/16727?source=see_link\">",
"     \"Overview of the treatment of stenosis and thrombotic complications of hemodialysis arteriovenous grafts and fistulas\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/48/7942?source=see_link\">",
"     \"Strategies other than treatment of stenosis to prevent thrombosis of hemodialysis vascular access grafts\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GENERAL ISSUES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Percutaneous angioplasty has become recognized as the standard of care with most dialysis programs. Nevertheless, when surgical revision and percutaneous angioplasty are directly compared, certain advantages and disadvantages associated with each of these modalities clearly emerge.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Surgical therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major advantage of surgery for venous stenosis is the elimination of the lesion. However, new lesions frequently emerge over time.",
"   </p>",
"   <p>",
"    The major disadvantage is the loss of potential venous access sites. Even a patch angioplasty, for example, results in the loss of a small portion of vein. Since venous stenosis is a recurrent problem, this may result in a progressive loss of venous anatomy available for access creation. Additional adverse effects include postoperative pain, the occasional need for a temporary access following the operation, and the inaccessibility of central veins to the surgeon.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Percutaneous angioplasty",
"    </span>",
"    &nbsp;&mdash;&nbsp;Percutaneous angioplasty has the principal advantage of preserving potential venous access sites. Additional benefits include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Since it is minimally invasive, there is also only mild post procedure discomfort.",
"     </li>",
"     <li>",
"      All venous sites are accessible, even those that are centrally located.",
"     </li>",
"     <li>",
"      There are lesions that can be easily treated that are otherwise relatively inoperable. In these cases, operative therapy results in either graft replacement or a major revision that bypasses the lesion by advancing the graft up the patient's arm or completely using another vein.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Angioplasty may not result in a permanent solution; lesions tend to be recurrent. In addition, some lesions cannot be successfully treated, thereby requiring surgical revision.",
"   </p>",
"   <p>",
"    A discussion of the relative patency rates after angioplasty and surgical therapy is presented below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     LOCATION OF LESIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;To best understand the problems that lead to dialysis-access dysfunction, it is important to recognize that the dialysis access actually consists of a complete circuit that begins and ends at the heart. It includes the arterial system that provides the feeding artery for the access, the access itself, and the venous system that provides drainage leading back to the heart. Problems anywhere within this system can affect flow within the access and lead to dysfunction.",
"   </p>",
"   <p>",
"    Venous stenosis, which is the most common culprit, occurs most frequently at the venous anastomosis, but may be observed anywhere within the venous system composed of the bridge graft, the anastomosis, and the draining veins (both peripheral and central). In a review of 2,300 cases of venous stenosis, the following distribution of stenotic lesions was found [",
"    <a class=\"abstract\" href=\"UTD.htm?17/37/18010/abstract/9\">",
"     9",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Venous anastomosis (60 percent)",
"     </li>",
"     <li>",
"      Peripheral vein (37.1 percent)",
"     </li>",
"     <li>",
"      Within the graft (38.4 percent)",
"     </li>",
"     <li>",
"      Central veins (3.2 percent)",
"     </li>",
"     <li>",
"      Multiple locations (31.3 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In contrast to venous problems, in-flow stenosis (on the arterial side) has been traditionally reported to occur in only a minority (0 to 4 percent) of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?17/37/18010/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. However, the problem appears to be in arriving at a standardized definition of what constitutes inflow stenosis (see below). There are data to suggest a significantly higher incidence of lesions on the arterial side of the circuit than previously reported:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One study of 40 patients with hemodialysis access provided via a synthetic graft and with a risk factor for arterial disease found that 11 cases (28 percent) had 13 arterial inflow lesions [",
"      <a class=\"abstract\" href=\"UTD.htm?17/37/18010/abstract/10\">",
"       10",
"      </a>",
"      ]. Ten of the lesions were at the arterial anastomosis, with two also having stenoses in the brachial artery. One patient had a single stenosis in the brachial artery.",
"     </li>",
"     <li>",
"      In another study involving 122 cases with arteriovenous grafts, inflow stenosis was identified in 36 (29 percent) cases [",
"      <a class=\"abstract\" href=\"UTD.htm?17/37/18010/abstract/11\">",
"       11",
"      </a>",
"      ]. These 36 cases involved 47 stenotic lesions, with the distribution being 8 arterial (6.6 percent of total cases), 29 artery-graft anastomosis (23.8 percent of total cases) and 10 juxta-anastomotic (8.2 percent of total cases). More than one lesion within the inflow segment was observed in 11 cases.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC CRITERIA FOR STENOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The criteria used for the diagnosis of stenosis are based upon a comparison with the adjacent vessel or graft [",
"    <a class=\"abstract\" href=\"UTD.htm?17/37/18010/abstract/2-7,12\">",
"     2-7,12",
"    </a>",
"    ]. At the",
"    <strong>",
"     venous",
"    </strong>",
"    anastomosis, there is often a significant size discrepancy between the graft and the adjacent \"normal\" vein. In this instance, the comparison used for the diagnosis should be the graft.",
"   </p>",
"   <p>",
"    The diagnosis of arterial anastomosis stenosis is difficult because there is a lack of a standardized definition. This is an artificially created orifice structure that lacks an optimal standard. Its size is based upon the surgeon's judgment and is generally smaller than the adjacent vessel. Some surgeons use a tapered graft that looks like a stenosis. In addition, there is always a major drop in pressure across this site.",
"   </p>",
"   <p>",
"    Basically, the inflow of the graft is composed of three parts, the artery adjacent to the graft, the anastomosis and the juxta-anastomotic access (two centimeters downstream from the arterial anastomosis). Stenosis of the artery and the juxta-anastomotic access can be easily determined by a size comparison with the adjacent normal vessel or graft. The problem lies with a definition of what constitutes stenosis of the artificially created anastomotic orifice. To solve this issue, it has been suggested that anastomosis stenosis be defined by a size comparison with the adjacent normal artery [",
"    <a class=\"abstract\" href=\"UTD.htm?17/37/18010/abstract/10\">",
"     10",
"    </a>",
"    ]. If the difference is 50 percent or more, it should be classified as stenotic.",
"   </p>",
"   <p>",
"    As far as the vessel itself is concerned, the 2006",
"    <span class=\"nowrap\">",
"     K/DOQI",
"    </span>",
"    hemodialysis access work group recommend that a hemodynamically significant stenosis requiring intervention should display a &ge;50 percent stenosis (as determined radiographically) plus evidence of a clinical or physiologic abnormality, such as [",
"    <a class=\"abstract\" href=\"UTD.htm?17/37/18010/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Abnormal physical findings",
"     </li>",
"     <li>",
"      Decreasing intragraft blood flow (less than 600",
"      <span class=\"nowrap\">",
"       mL/min)",
"      </span>",
"     </li>",
"     <li>",
"      Elevated static pressure within the graft",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     NATURE OF LESIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The type of stenotic lesion varies in part with the specific area of involvement:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A stenotic lesion located in a peripheral vein may vary markedly in length. The lesion may consist of single or multiple short foci, frequently corresponding to the expected sites and appearance of valves. It may also involve a long segment of the vein, occasionally exceeding 40 cm in length [",
"      <a class=\"abstract\" href=\"UTD.htm?17/37/18010/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Although stenosis within the graft can occur anywhere within the graft, its frequency is not uniformly distributed. With loop grafts, the changes principally occur on the venous side of the loop. By comparison, in straight grafts, the involvement generally spares the portion of the graft immediately adjacent to the arterial anastomosis.",
"     </li>",
"     <li>",
"      Central venous stenosis may be observed within the subclavian, brachiocephalic, or superior vena cava veins. It is primarily related to the previous use of tunneled central venous dialysis catheters; however, other types of devices such as temporary catheters and cardiac pacemaker wires placed within the central veins can result in stenosis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/32/39432?source=see_link\">",
"       \"Central vein stenosis associated with dialysis access\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Central venous stenosis may occasionally be observed without any identifiable antecedent [",
"    <a class=\"abstract\" href=\"UTD.htm?17/37/18010/abstract/2,13\">",
"     2,13",
"    </a>",
"    ]. In a cohort of 69 consecutive patients undergoing percutaneous placement of tunneled right internal jugular vein catheters, venography was performed to identify central vein anatomical abnormalities [",
"    <a class=\"abstract\" href=\"UTD.htm?17/37/18010/abstract/13\">",
"     13",
"    </a>",
"    ]. In 29 cases (42 percent), venography showed evidence of unexpected stenosis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    angulation of the central veins. Although abnormalities were more common in those patients who had previously had tunneled internal jugular catheters, problems were observed in 14 of the 46 cases (30 percent) that had not had catheters previously.",
"   </p>",
"   <p>",
"    The most common lesion causing venous stenosis is neointimal hyperplasia [",
"    <a class=\"abstract\" href=\"UTD.htm?17/37/18010/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]&nbsp;(",
"    <a class=\"graphic graphic_picture graphicRef62250 \" href=\"UTD.htm?27/20/27972\">",
"     picture 1",
"    </a>",
"    ). This is particularly true with anastomotic lesions and lesions at the site of venous valves. Perivenous fibrosis and phlebosclerosis appear to be responsible for venous lesions in other sites in the peripheral veins and are the most likely cause of the lesion observed in central veins.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     ANGIOPLASTY THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since it is safe, effective, and easily performed, angioplasty has become a standard therapy for the management of venous stenosis affecting dialysis access grafts [",
"    <a class=\"abstract\" href=\"UTD.htm?17/37/18010/abstract/2-7,16\">",
"     2-7,16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Procedure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Percutaneous angioplasty treatment of venous stenosis is an outpatient procedure, with the access immediately available for dialysis once the lesion is corrected. Lesions in all locations within the PBG and its draining veins, both peripheral and central, can be easily, effectively, and safely treated [",
"    <a class=\"abstract\" href=\"UTD.htm?17/37/18010/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Direct fluoroscopic observation is necessary to perform angioplasty, with digital capability being very advantageous. Heparinization is unnecessary because of the high blood flow that is present in the access.",
"   </p>",
"   <p>",
"    During dilatation, flow is occluded for only short intermittent periods, and clotting of the access therefore rarely occurs. Because the procedure is potentially very painful, the patient requires adequate sedation.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/60/4042?source=see_link\">",
"     Midazolam",
"    </a>",
"    hydrochloride, alone or in combination with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/52/38730?source=see_link\">",
"     fentanyl",
"    </a>",
"    , has been used to produce a state of relaxation for the 5 to 10 minutes required to perform the treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?17/37/18010/abstract/9\">",
"     9",
"    </a>",
"    ]. Patients must be monitored very closely during this process. Since the requirement for adequate sedation varies considerably, the dosage must be carefully titrated.",
"   </p>",
"   <p>",
"    The specific steps of the procedure are as follows:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Pre-procedure evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to a general history and physical examination directed toward the risk of the procedure, a specific, detailed physical examination of the access and access arm should be performed [",
"    <a class=\"abstract\" href=\"UTD.htm?17/37/18010/abstract/17\">",
"     17",
"    </a>",
"    ]. This examination is important for several reasons.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Although the patient should have been sent for a valid reason, it is wise to be assured that a problem is actually present before initiating the procedure. A dysfunctional access should be obvious by physical examination.",
"     </li>",
"     <li>",
"      Evaluating the access will help in planning the approach to the procedure.",
"     </li>",
"     <li>",
"      It will serve as a comparison for evaluating the access after the procedure is complete",
"     </li>",
"     <li>",
"      It is necessary for detecting the presence of a contraindication to the procedure.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Accessing the graft",
"    </span>",
"    &nbsp;&mdash;&nbsp;An intravascular sheath (either 6 or 7 French) should be used for this procedure. Although the angioplasty balloon can be easily introduced without a sheath, it is essential that the affected site be evaluated after treatment, prior to removal of the guidewire. This can be most easily accomplished if an intravascular sheath is in place.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Preprocedure angiogram",
"    </span>",
"    &nbsp;&mdash;&nbsp;An angiogram is performed to evaluate the anatomy of the graft and its draining veins up through the superior vena cava. It is important that the entire circuit be evaluated since multiple lesions are seen in one-third of the cases [",
"    <a class=\"abstract\" href=\"UTD.htm?17/37/18010/abstract/2\">",
"     2",
"    </a>",
"    ]. All lesions should be documented for later reference. It is also important to evaluate the arterial portion of the circuit by looking at the arterial anastomosis, and adjacent feeding artery. This can be easily accomplished through a retrograde arteriogram performed by injecting radiocontrast while manually occluding the access downstream from the injection site.",
"   </p>",
"   <p>",
"    This imaging is usually accomplished using radio-contrast; however, other agents have been used. Gadolinium should be avoided, since the administration of this agent during magnetic resonance studies has been strongly linked to an often severe disease called nephrogenic systemic fibrosis among patients with moderate to severe renal disease, particularly those requiring dialysis. As a result, it is recommended that gadolinium-based imaging be avoided, if possible, in dialysis patients and those with an estimated glomerular filtration rate less than 30",
"    <span class=\"nowrap\">",
"     mL/min.",
"    </span>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/22/31082?source=see_link\">",
"     \"Nephrogenic systemic fibrosis/nephrogenic fibrosing dermopathy in advanced renal failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Passing guidewire",
"    </span>",
"    &nbsp;&mdash;&nbsp;A guidewire is then passed through the sheath and is advanced up to the level of the central veins. The inability to pass the guidewire precludes correction of the lesion with angioplasty. In cases where the vein is tortuous, guidewire manipulation may be required, which can be a considerable challenge.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Balloon introduction",
"    </span>",
"    &nbsp;&mdash;&nbsp;The angioplasty balloon catheter is passed over the guidewire and advanced to the most proximal lesion. Additional lesions, if present, are treated by moving peripherally in the extremity. If a central venous lesion is present, it is not",
"    <strong>",
"     generally",
"    </strong>",
"    addressed until the peripheral lesion treatments are complete.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Angioplasty",
"    </span>",
"    &nbsp;&mdash;&nbsp;The basic technique of angioplasty as applied to the access graft and associated venous drainage system is dependent upon the use of large diameter, high-pressure balloon catheters. The balloon size should be selected according to the size of the vessels observed in the individual patient and should be over-sized to the vessel by 20 to 30 percent. Unless the veins are of unusual size, a 7 to 8 mm balloon will be appropriate for both the graft and peripheral veins and a 12 to 14 mm balloon will be needed centrally (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef54796 \" href=\"UTD.htm?1/28/1472\">",
"     image 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    A pressure of 10 atmospheres (atm) is routinely utilized. If this is not effective in breaking the lesion, pressures of 15 and 20 atm are sequentially applied. Multiple dilatations may be necessary for resistant lesions. The angioplasty balloons that are routinely used are referred to as high-pressure balloons. These balloons generally have a manufacturer's assigned burst-pressure of 16 atm.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Ultrahigh pressure balloons",
"    </span>",
"    &nbsp;&mdash;&nbsp;Balloons referred to as \"ultrahigh pressure\" are also available. These devices have a manufacturer's assigned burst-pressure in the range of 30 atm; however, they are being used successfully at pressures up to 40 atm. In a study regarding dilation pressures necessary to perform successful angioplasty, it was found that 55 percent of lesions required balloon inflation pressures greater than 15 atm to efface the waist of the stenosis [",
"    <a class=\"abstract\" href=\"UTD.htm?17/37/18010/abstract/18\">",
"     18",
"    </a>",
"    ]. Excluding initial failures, 20 percent of lesions in native fistulas and 9 percent in grafts required very high pressure (&gt;20 atm) to efface the waist. A total of 230 lesions were treated. Two (one percent) could not be successfully treated with PTA despite the use of \"ultra high\" pressure (approximately 40 atm). High pressure was needed less frequently in PTA procedures performed in the setting of thrombectomy procedures than in prophylactic PTA procedures. Residual stenosis was positively correlated with severity of initial stenosis and negatively correlated with duration of inflation.",
"   </p>",
"   <p>",
"    Use of these \"ultra high pressure\" balloons has markedly reduced the incidence of \"resistant\" lesions. In one study of 87 patients with venous stenosis treated with standard high-pressure balloons, 7 cases (8 percent) were resistant to dilatation. Using the newer ultrahigh pressure design, 100 percent success was obtained in these cases [",
"    <a class=\"abstract\" href=\"UTD.htm?17/37/18010/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The advent of this new balloon design is very important. It basically means that lesions that could not be dilated before can now be effectively treated. It also makes the opinion-based definition of successful angioplasty of a 30 percent or less residual obsolete. Based upon cost considerations, the ultrahigh pressure design might be a good candidate for the standard balloon to be used in the interventional laboratory.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Cutting angioplasty balloon",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several reports of the use of a cutting angioplasty balloon (CAB) to treat resistant lesions. Most of these reports are hampered by being retrospective, uncontrolled, or of such small size that meaningful conclusions are impossible. There are, however, a few reasonably designed studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a prospective, multicenter clinical trial, 340 patients with stenotic or thrombosed hemodialysis grafts were randomly assigned to receive treatment with cutting balloon (CB) or standard angioplasty (PTA) for venous outflow stenosis [",
"      <a class=\"abstract\" href=\"UTD.htm?17/37/18010/abstract/20\">",
"       20",
"      </a>",
"      ]. At follow-up at six months, the procedural success rates were similar with both techniques (81 and 75 percent for the CB and PTA groups, respectively). With CB, the primary patency rates of the target lesions were 84 percent, 66 percent, and 48 percent at one, three, and six months, respectively. With PTA, the primary patency rates of the target lesions were 78 percent, 63 percent, and 21 percent at one, three, and six months, respectively. There was no difference in the six month primary patency rates in the target lesion.",
"     </li>",
"     <li>",
"      A prospective controlled study was conducted to compare primary patency rates for CAB angioplasty (CAB PTA) and conventional balloon PTA (conventional PTA) in the treatment of different types of hemodialysis access stenosis [",
"      <a class=\"abstract\" href=\"UTD.htm?17/37/18010/abstract/21\">",
"       21",
"      </a>",
"      ]. Patients in whom treatment with CAB PTA alone or conventional PTA alone was clinically successful were compared. Primary patency for the lesion was defined as uninterrupted patency of the treated site after balloon PTA. The CAB PTA group consisted of 62 patients with 77 stenoses, while the conventional PTA group contained 52 patients with 68 stenoses. In patients with either autogenous venous stenosis, intragraft stenosis or in-stent restenosis, no significant difference in the primary patency rate was noted between the two groups. However, in patients with graft-to-vein anastomotic stenosis, the primary patency rate was significantly higher for CAB PTA than for conventional PTA.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    From these studies, it appears that CAB is safe; however, whether or not it offers an advantage over other approaches remains to be demonstrated. Additional controlled, prospective studies based on a large cohort of patients are needed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Post-procedure evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once the venous lesions have been treated, it is important that the guidewire be left in place until the result of the angioplasty can be evaluated. If there is a complication, the presence of the guidewire may be essential for successful management.",
"   </p>",
"   <p>",
"    Following angioplasty, an angiogram should be performed to assess and document the result of therapy (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef52331 \" href=\"UTD.htm?14/62/15328\">",
"     image 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef65660 \" href=\"UTD.htm?21/34/22063\">",
"     image 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef80782 \" href=\"UTD.htm?9/29/9695\">",
"     picture 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef74325 \" href=\"UTD.htm?35/34/36399\">",
"     image 4",
"    </a>",
"    ) and identify the presence of any complications that might have occurred. Since some venous lesions are elastic and recoil after dilatation, it is advisable to wait 5 to 10 minutes after angioplasty to check the result of the treatment.",
"   </p>",
"   <p>",
"    It is important to assess inflow when assessing a dysfunctional graft. There are two easy ways to do this short of resorting to expensive technology: visually assessing flow rate and checking augmentation.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Visual assessment of access flow &mdash; With experience, it is possible to assess the speed of blood flow within the graft (or fistula) by observing the speed of the movement of a puff of radiocontrast as it traverses the access. To do this, it is important that one observe both the front end (beginning) and the back end (ending) of a short bolus of radiocontrast, if either is not seen, one gets the impression that there is no movement. This is a subjective assessment, but with experience it becomes a valuable tool.",
"     </li>",
"     <li>",
"      Augmentation &mdash; This is perhaps the best method to use for inflow assessment. It will be discussed in more detail in the section dealing with physical examination. It is performed by simply feeling of the pulse within the graft (or fistula) and then, using this as the baseline, completely occlude the graft and see how much the pulse increases (augments). Again, with experience, this becomes a very useful tool for assessing inflow",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If your assessment of inflow using these two methods suggests that it is not optimum, then a careful evaluation of the arterial anastomosis and feeding artery is indicated, although most interventionalists advocate assessing the inflow routinely in all cases. (It should not be coded unless there is a medical indication for the study). If an arterial inflow lesion is detected, it should be treated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Hemostasis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hemostasis can be obtained with manual pressure. The use of an adhesive bandage (Tip Stop, Gambro-Hospal) having a small plastic button covered with a layer of collagen in its center is advantageous for this purpose. The button applies pressure and the collagen promotes thrombosis. These bandages are relatively inexpensive and very effective in most cases. Using this device, hemostasis can be accomplished within three to five minutes. Some interventionalists prefer to use a purse string type of suture at the cannulation site [",
"    <a class=\"abstract\" href=\"UTD.htm?17/37/18010/abstract/22\">",
"     22",
"    </a>",
"    ]. If a suture is placed, provision must be made for removal within 24 to 48 hours, failure to do so can lead to skin necrosis and place the graft at risk for infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     JUDGING THE SUCCESS OF ANGIOPLASTY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some mechanism must be used to determine that an angioplasty treatment was effective, as many lesions are elastic (or at least relatively so) and recoil after what appeared to initially be an effective dilatation. This can happen immediately or it can occur over a period of days. Residual stenosis (stenosis not completely removed by the angioplasty treatment) can adversely affect outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?17/37/18010/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are several parameters that can be used to judge the success of therapy. All should be applied.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Anatomic criteria",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 2006",
"    <span class=\"nowrap\">",
"     NKF-K/DOQI",
"    </span>",
"    Guideline workgroup defined anatomical success as no more than 30 percent residual stenosis remaining (as compared with the adjacent normal vein) following angioplasty treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?17/37/18010/abstract/24\">",
"     24",
"    </a>",
"    ]. However, the following studies addressing residual stenosis demonstrate that this definition should be changed since supposedly successful dilatations have definitive hemodynamic problems. Instead, the goal should be no residual stenosis.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study of 50 successful angioplasty procedures (as defined by",
"      <span class=\"nowrap\">",
"       K/DOQI)",
"      </span>",
"      performed on 32 patients with significant initial venous stenosis (&gt;50 percent), pullback pressure measurements were obtained from the superior vena cava to the graft to identify hemodynamically significant (&gt; 10 mm Hg) stenoses [",
"      <a class=\"abstract\" href=\"UTD.htm?17/37/18010/abstract/25\">",
"       25",
"      </a>",
"      ]. Hemodynamically significant stenoses with a gradient range of 10 to 27 mmHg (mean of 16 mmHg) were found in nine (18 percent) of 50 procedures. All gradients occurred at sites of previous angioplasty. Repeated angioplasty of these stenoses performed with larger angioplasty balloons reduced gradients to less than 3 mm Hg in six stenoses and to 5 mm Hg in three stenoses.",
"     </li>",
"     <li>",
"      In a prospective study of 330 angioplasty procedures designed to identify predictors of arteriovenous graft patency after radiologic intervention, the median graft survival was found to be inversely related to the magnitude of residual stenosis [",
"      <a class=\"abstract\" href=\"UTD.htm?17/37/18010/abstract/23\">",
"       23",
"      </a>",
"      ]. With complete resolution, the primary patency was 6.9 months; by comparison, it was reduced to 4.6 months with residual stenosis. In addition, median intervention-free graft survival after angioplasty was inversely related to the postangioplasty intra-graft to systemic systolic pressure ratio (static venous pressure).",
"     </li>",
"     <li>",
"      In a prospective study of 358 fistulograms of grafts and 185 in fistulas, the degree of stenosis post-angioplasty and the intervention-free survival were similar in both grafts and fistulas [",
"      <a class=\"abstract\" href=\"UTD.htm?17/37/18010/abstract/26\">",
"       26",
"      </a>",
"      ]. Based upon multivariable regression analysis, residual access stenosis (among other factors) was significantly associated with shorter access patency after angioplasty.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Clinical criteria",
"    </span>",
"    &nbsp;&mdash;&nbsp;Physical examination is a very useful and accurate method for detecting problems affecting the vascular access [",
"    <a class=\"abstract\" href=\"UTD.htm?17/37/18010/abstract/17\">",
"     17",
"    </a>",
"    ]. The abnormalities evident in the presence of significant pathology prior to treatment should not be apparent in its absence following treatment. In practical terms, one should feel a palpable continuous, soft thrill over the graft with a soft compressible pulse following successful balloon angioplasty.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Hemodynamic/physiologic criteria",
"    </span>",
"    &nbsp;&mdash;&nbsp;According to",
"    <span class=\"nowrap\">",
"     NKF-K/DOQI",
"    </span>",
"    Guidelines, a patient should not be sent for angioplasty unless there are hemodynamic or physiologic abnormalities [",
"    <a class=\"abstract\" href=\"UTD.htm?17/37/18010/abstract/24\">",
"     24",
"    </a>",
"    ]. These abnormal clinical parameters should return to within acceptable limits following intervention.",
"   </p>",
"   <p>",
"    Reports have indicated that approximately one third of patients fail to show an increase in blood flow after what had been judged to be a successful angioplasty [",
"    <a class=\"abstract\" href=\"UTD.htm?17/37/18010/abstract/27-29\">",
"     27-29",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study in which changes in access flow were used as the surveillance modality to detect venous stenosis, treatment success was defined as the ability to increase flow by more than 20 percent of the baseline measured within one week post-procedure [",
"      <a class=\"abstract\" href=\"UTD.htm?17/37/18010/abstract/27\">",
"       27",
"      </a>",
"      ]. Failure to restore access flow by this amount following intervention occurred in 21 percent of grafts treated by angioplasty. When flow was not successfully restored, thrombosis ensued. The reasons for this hemodynamic failure are not clear, but could very well be factors such as residual stenosis, elasticity of the lesion, or even a failure to diagnose arterial inflow lesions.",
"     </li>",
"     <li>",
"      In a 12 month study of 31 patients having angioplasty performed on an arteriovenous graft, a blood flow rate after angioplasty of less than 1000",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      was found to be more likely to require repeat intervention and to exhibit thrombosis within the first six months compared with those with flow rates greater than 1000",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?17/37/18010/abstract/30\">",
"       30",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The abnormalities that suggested the presence of the stenotic lesion prior to therapy should be reassessed as soon as practical following treatment. A failure of indices to return to normal or near normal indicates treatment failure and the need for alternative treatment. The reason for these early failures is not totally clear; however, recoil related to the presence of an elastic lesion is the most likely culprit.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     PATENCY RATES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patency rates with angioplasty vary largely based upon the type of vessel treated and the period of follow-up:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Initial success rates have ranged from 80 to 98 percent for arteriovenous grafts [",
"      <a class=\"abstract\" href=\"UTD.htm?17/37/18010/abstract/2,3,8,9,31-33\">",
"       2,3,8,9,31-33",
"      </a>",
"      ]. There are only a few small studies available that present data derived strictly from fistulas. These have reported an initial success rate ranging from 89.5 percent to 97 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?17/37/18010/abstract/34-38\">",
"       34-38",
"      </a>",
"      ]. The largest of these involved a series of 1561 cases, which had a 97 percent success rate [",
"      <a class=\"abstract\" href=\"UTD.htm?17/37/18010/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Long-term success rates are generally listed as either primary or unassisted rates (primary or unassisted patency refers to that period from the time the procedure is performed until a second procedure is required to maintain patency). Unassisted patency rates for angioplasty generally range from 41 to 76 percent at six months and 31 to 45 percent at one year [",
"      <a class=\"abstract\" href=\"UTD.htm?17/37/18010/abstract/2,9,31,32\">",
"       2,9,31,32",
"      </a>",
"      ]. As with immediate outcomes, the treatment of central lesions is also associated with relatively poorer long-term success (approximately 25 percent at six months [",
"      <a class=\"abstract\" href=\"UTD.htm?17/37/18010/abstract/2\">",
"       2",
"      </a>",
"      ]).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There is a tendency for venous stenosis problems to be recurrent, making repeat therapy necessary. In one series, for example, it was found that once successfully performed, repeat angioplasty was required at a mean 5.8 month intervals in order to maintain graft flow at acceptable levels [",
"    <a class=\"abstract\" href=\"UTD.htm?17/37/18010/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Little is known about the factors that determine the duration of patency following an angioplasty procedure. In one study of 330 cases of angioplasty, the median primary patency for a graft following angioplasty was longer when there was no residual stenosis than if there was any degree of residual stenosis [",
"    <a class=\"abstract\" href=\"UTD.htm?17/37/18010/abstract/23\">",
"     23",
"    </a>",
"    ]. With complete resolution, the primary patency was 6.9 months; with residual stenosis, it was reduced to 4.6 months.",
"   </p>",
"   <p>",
"    At least part of the problem appears to be related to elasticity since the lesions recoil. At times, this happens rather quickly in minutes to hours. If the lesion recoils, the therapeutic benefit of the treatment is obviated making repeat therapy necessary. For this reason, one should wait at least 10 to 15 minutes after performing an angioplasty treatment to assess the result to allow for any immediate recoil to occur. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Post-procedure evaluation'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Treatment of arterial lesions has also been successful. In one report, 33 patients with arterial inflow lesions were treated by angioplasty (18 arteriovenous fistulae and 17 PTFE grafts) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/37/18010/abstract/39\">",
"     39",
"    </a>",
"    ]. Angioplasty was performed in 22 radial, 10 brachial, and seven ulnar arteries. Treatment was successful (residual of 30 percent or less) in all but one patient. There were no complications. Primary and secondary patencies were 63.5 and 90.6 percent at six months and 40.8 and 75.6 percent at 24 months, respectively.",
"   </p>",
"   <p>",
"    As previously mentioned, the",
"    <span class=\"nowrap\">",
"     NKF-K/DOQI",
"    </span>",
"    guidelines state that the expected six-month primary patency rate for the treatment of dialysis access graft dysfunction treated by percutaneous angioplasty should be at least 50 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?17/37/18010/abstract/24\">",
"     24",
"    </a>",
"    ]. This should be regarded as a minimum criterion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     SPECIAL CONSIDERATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several special circumstances that should be addressed concerning lesions that are treated with percutaneous angioplasty.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Character of the lesion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Considerable variety is seen in the character of venous stenosis lesions relating to location, length, severity of narrowing, and number of stenotic sites. There is nothing to suggest that primary treatment via angioplasty should be avoided in any of these specific lesions. In a previously cited study, the duration of unassisted patency for each category of lesion studied was statistically comparable to that for the total group [",
"    <a class=\"abstract\" href=\"UTD.htm?17/37/18010/abstract/2\">",
"     2",
"    </a>",
"    ]. No significant differences were seen for length of lesion, multiple lesions, or location of the lesion. Although severity of the stenosis was not specifically evaluated in this study, it has not proven to be a determining factor for angioplasty success.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Recurrent lesions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although venous stenotic lesions tend to recur, repeat therapy for recurrent lesions is successful:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a large series of cases that included those with multiple angioplasties, a numerical decrease in primary patency that was not statistically significant was seen between 285 cases with 1 treatment, 130 with 2, and 66 with 3 treatments [",
"      <a class=\"abstract\" href=\"UTD.htm?17/37/18010/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Using access flow measurements to assess the effect of angioplasty, another study found no significant difference in either the absolute or the percentage of improvement in access blood flow in 13 patients that required repeat angioplasties [",
"      <a class=\"abstract\" href=\"UTD.htm?17/37/18010/abstract/39\">",
"       39",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Frequent recurrences",
"    </span>",
"    &nbsp;&mdash;&nbsp;The",
"    <span class=\"nowrap\">",
"     NKF-K/DOQI",
"    </span>",
"    guidelines state that if repeat angioplasty is required more than twice within three months, the patient should be referred for surgical revision [",
"    <a class=\"abstract\" href=\"UTD.htm?17/37/18010/abstract/24\">",
"     24",
"    </a>",
"    ]. This recommendation has considerable validity. If a lesion is recurring at a frequent interval, elasticity of the lesion is often the cause and an alternative to what has been previously done should be sought. The alternatives are surgery or the placement of a stent.",
"   </p>",
"   <p>",
"    Some type of anatomical disruption, such as a break or tear, accompanies a successful angioplasty. If only stretching occurs, the likelihood of recoil is present which will result in inadequate post angioplasty results [",
"    <a class=\"abstract\" href=\"UTD.htm?17/37/18010/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are several alternatives if the problem is elastic recoil:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If there was not total effacement of the angioplasty balloon when it was initially dilated within the lesion, the first approach that should be tried is more pressure. It is important to obtain complete effacement with no residual stenosis. If the balloon that is being used is not adequate to the task, it will probably be ruptured in this process. In this setting, the clinician should switch to an ultrahigh pressure balloon. One must keep in mind, however; that any time higher pressure is used, there is some risk of venous rupture.",
"      <br/>",
"      <br/>",
"      In general, venous angioplasty is more effective if the vessel is over-dilated by 20 to 30 percent. If total balloon effacement was obtained, but recoil is observed following dilatation, it is possible that a larger balloon might result in the type of anatomical disruption that would provide success. The obvious problem is the increased risk of venous rupture with a larger balloon. This risk must be weighed against the fact that if the lesion cannot be successfully resolved, either with angioplasty or angioplasty plus stenting, the case will need to go to surgery.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Use of endoluminal stent",
"    </span>",
"    &nbsp;&mdash;&nbsp;A peripheral lesion that has failed balloon angioplasty may be considered an indication for the placement of a stent. This is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/42/11944?source=see_link\">",
"     \"Use of stents for venous stenosis associated with dialysis vascular access\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Surgical revision",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy of surgical treatment has been both lauded and questioned. In a surgical study conducted over a two year period, 101 operative procedures were performed on failed grafts [",
"    <a class=\"abstract\" href=\"UTD.htm?17/37/18010/abstract/41\">",
"     41",
"    </a>",
"    ]. All cases had previously been treated with percutaneous dilatation. The number of previous interventions ranged from one to five. Primary patency rates of the angioaccess grafts following surgical revision were 43, 24, and 12 percent at 30, 60, and 90 days, respectively. These surgical investigators concluded that surgical intervention did not significantly prolong the patency of angioaccess grafts that have previously failed percutaneous interventions.",
"   </p>",
"   <p>",
"    Nevertheless, in cases with frequent recurrences following what has appeared to be successful angioplasty treatment, an alternative must be sought. Ultimately, surgery may be required. Therefore, if stenting is used first, one must be sure that it will not make surgery at a later date more difficult or impossible.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h1\">",
"     PROCEDURE RELATED COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;As with any type of medical procedure, angioplasty can result in procedure related complications; however, the complication rate that has been reported is low. Procedure related complications are generally classified according to the reporting standards of the Society for Interventional Radiology [",
"    <a class=\"abstract\" href=\"UTD.htm?17/37/18010/abstract/42\">",
"     42",
"    </a>",
"    ]. According to this standard, all complications, including pulmonary and cardiac events that occur within 30 days following the procedure are considered procedure related. Minor complications are those that require either no therapy or only nominal therapy and resolved without any adverse consequence. Major complications are defined as those that require an increase in the level of care, or result in hospitalization, permanent adverse sequelae or death.",
"   </p>",
"   <p>",
"    In a report of 3,560 cases of dialysis access graft angioplasty performed by 29 interventional nephrologists in 11 different freestanding facilities, the overall complication rate was reported to be 1.15 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?17/37/18010/abstract/43\">",
"     43",
"    </a>",
"    ]. Of these, 1.04 percent were minor.",
"   </p>",
"   <p>",
"    The most frequent procedure related complication seen in association with angioplasty that dictates the need for intervention is tearing of the vein or vein rupture [",
"    <a class=\"abstract\" href=\"UTD.htm?17/37/18010/abstract/44\">",
"     44",
"    </a>",
"    ]. Although some investigators have reported an alarmingly high incidence of vein rupture in association with angioplasty treatment of autologous fistulae, the occurrence has been relatively low in our experience [",
"    <a class=\"abstract\" href=\"UTD.htm?17/37/18010/abstract/18\">",
"     18",
"    </a>",
"    ]. In the large series previously mentioned, the incidence of vein rupture was 0.9 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?17/37/18010/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical significance of this complication is variable, ranging from none to disaster for the access. The difference lies in the severity of the tear. The presence of this complicating event is heralded by the extravasation of contrast, blood or both. Small extravasations are of no clinical significance. It is not unusual to observe a small ecchymosis over the treated site the day following therapy. There may be tenderness at the site as well. It is obvious that a small, subclinical extravasation of blood has occurred. These are of no consequence, and most are totally missed except by the patient who may not mention it. Nothing need be done except to reassure the patient. They need not be listed as a complication, although it is obvious that a small break has occurred.",
"   </p>",
"   <p>",
"    Vein rupture with extravasation becomes more obvious when there is either the extravasation of contrast creating an image on fluoroscopy or the formation of an obvious hematoma. These occurrences should be tabulated as procedure-related complications.",
"   </p>",
"   <p>",
"    Clinical problems occur when the extravasation is associated with the formation of a hematoma, which occurs when blood has extravasated and accumulated in a significant amount. A hematoma is always listed as a procedure-related complication; however, its clinical consequence may range from minimal to major. The amount of extravasated contrast associated with the hematoma may be minimal or absent. We have found it useful to use a classification system for extravasation based upon their clinical significance [",
"    <a class=\"abstract\" href=\"UTD.htm?17/37/18010/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H33\">",
"     'Hematomas'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Subclinical extravasation of contrast",
"    </span>",
"    &nbsp;&mdash;&nbsp;Occasionally, during the course of an angioplasty procedure, a blush of contrast adjacent to the vein at the site of the dilatation is observed but there is no associated hematoma. As is the case with blood, this small extravasation is subclinical in that it is asymptomatic and only obvious on fluoroscopy. It takes on significance because it is immediately obvious on the fluoroscopic image. A subclinical extravasation of contrast (SEC) should be listed as a minor complication.",
"   </p>",
"   <p>",
"    Although SEC is listed as a complication because it is immediately obvious, it is of no clinical consequence. No treatment is required.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Hematomas",
"    </span>",
"    &nbsp;&mdash;&nbsp;When a hematoma is noted, one must make two determinations: is it stable or continuing to enlarge? and does it affect flow?",
"   </p>",
"   <p>",
"    This results in the following definitions:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A grade 1 hematoma is stable, eg, not continuing to grow, and does not affect flow.",
"     </li>",
"     <li>",
"      A grade 2 hematoma is a hematoma that is stable but affects flow",
"     </li>",
"     <li>",
"      A grade 3 hematoma is an unstable hematoma. It is a catastrophic event resulting from a complete or near complete rupture (or dehiscence) of the vein.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h3\">",
"     Grade 1",
"    </span>",
"    &nbsp;&mdash;&nbsp;A grade 1 hematoma is stable, eg, not continuing to grow, and does not affect flow. In the large angioplasty series previously mentioned [",
"    <a class=\"abstract\" href=\"UTD.htm?17/37/18010/abstract/43\">",
"     43",
"    </a>",
"    ], the incidence of a grade 1 hematoma was 0.76 percent (27 cases out of 3,560). This is generally the most frequent complication observed.",
"   </p>",
"   <p>",
"    Although the grade 1 situation causes concern on the part of the operator and the patient, it is of no real consequence to the outcome of the procedure and requires no specific treatment. This is true regardless of its size. A grade 1 hematoma is a minor complication.",
"   </p>",
"   <p>",
"    The patient with a grade 1 hematoma will have an ecchymosis and will need reassurance and may require symptomatic treatment measures [",
"    <a class=\"abstract\" href=\"UTD.htm?17/37/18010/abstract/7\">",
"     7",
"    </a>",
"    ]. Localized patient discomfort may be significant and may last for several days. Mild analgesics and a heating pad may be helpful. The resulting ecchymosis may be quite large, depending on the size of the hematoma.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h3\">",
"     Grade 2",
"    </span>",
"    &nbsp;&mdash;&nbsp;If a hematoma is stable but affects flow it is classified as a grade 2 hematoma. This is not strictly dependent upon size. Most of these lesions stabilize very quickly after they form. If they do not, they will soon develop into a grade 3 extravasation. The grade 2 hematoma is classified as a minor complication if it is successfully treated. It is classified as a major complication if the access is lost. In the series mentioned previously [",
"    <a class=\"abstract\" href=\"UTD.htm?17/37/18010/abstract/43\">",
"     43",
"    </a>",
"    ], the incidence of this complication was 0.11 percent (4 cases out of 3,560).",
"   </p>",
"   <p>",
"    With a grade 2 hematoma, it appears that the tear in the wall of the vessel is being displaced into the former lumen resulting in its obstruction. The goal of treatment is to press the tear outward to open the lumen and restore flow. It appears that if the lumen is opened with an angioplasty balloon, the pressure of the balloon will frequently stabilize the situation after a few minutes and allow for the restoration of flow.",
"   </p>",
"   <p>",
"    This treatment requires that a guidewire be positioned across the lesion. For this reason, it is recommended that the guidewire never be removed after an angioplasty until the treated lesion has been evaluated for complications. The angioplasty balloon is passed over the guidewire and positioned over the site of the tear. Once in position, the balloon should then be inflated with a low pressure, only the amount necessary to fully expand the balloon should be applied.",
"   </p>",
"   <p>",
"    The inflated balloon is left in place for four to five minutes. This is done to plaster the torn endothelial surfaces against the wall and to displace the compressing hematoma. After the required time, deflate the balloon and remove it gently. The site is checked using a puff of radiocontrast to see if flow is now present. If flow appears normal or relatively so and the hematoma is stable, nothing further needs to be done. If flow continues to be significantly affected, consider inserting an endovascular stent [",
"    <a class=\"abstract\" href=\"UTD.htm?17/37/18010/abstract/45,46\">",
"     45,46",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h3\">",
"     Grade 3",
"    </span>",
"    &nbsp;&mdash;&nbsp;A grade 3 hematoma is an unstable hematoma. It is a catastrophic event resulting from a complete or near complete rupture (or dehiscence) of the vein. Hematoma formation generally occurs very rapidly. The size of the hematoma, however, is quite variable. It depends on how quickly the condition is recognized and controlled.",
"   </p>",
"   <p>",
"    When a grade 3 hematoma occurs, the access is generally lost. It is always classified as a major complication. In the series previously mentioned [",
"    <a class=\"abstract\" href=\"UTD.htm?17/37/18010/abstract/43\">",
"     43",
"    </a>",
"    ], the incidence of this complication was 2 cases out of 3,560 procedures.",
"   </p>",
"   <p>",
"    The primary goal in the management of a grade 3 hematoma is to arrest a progressing process. This is critical to limit the size of the hematoma. The hematoma begins, expands rapidly, and is pulsatile. Arterial blood is being pumped directly into the tissue surrounding the area. Early recognition is critical, but not always easy. It can be diagnosed by palpating the area just dilated. A rapidly expanding, pulsatile hematoma will be evident.",
"   </p>",
"   <p>",
"    As soon as the situation is recognized, the access should be occluded [",
"    <a class=\"abstract\" href=\"UTD.htm?17/37/18010/abstract/7\">",
"     7",
"    </a>",
"    ]. To occlude the access, simply inflate the angioplasty balloon to a low pressure within the access below the site of rupture. There have been some reports in which the access has been salvaged in the face of a serious vein rupture by using a stent [",
"    <a class=\"abstract\" href=\"UTD.htm?17/37/18010/abstract/47,48\">",
"     47,48",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h1\">",
"     BENEFITS OF PROSPECTIVE TREATMENT OF VENOUS STENOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Angioplasty treatment of venous stenosis is based upon prospective monitoring for increasing stenosis is effective, resulting in a decreased incidence of thrombosis and extended survival of the graft. As examples [",
"    <a class=\"abstract\" href=\"UTD.htm?17/37/18010/abstract/33,44,49-53\">",
"     33,44,49-53",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Over an 8 year period in one study, a 70 percent decrease in the thrombosis rate was reported in which an intensive graft maintenance protocol utilizing angioplasty was followed [",
"      <a class=\"abstract\" href=\"UTD.htm?17/37/18010/abstract/52\">",
"       52",
"      </a>",
"      ]. During this period, there was also nearly an eightfold decrease in the access replacement rate, and the average age of the patent usable accesses increased from approximately two to three years.",
"     </li>",
"     <li>",
"      In a second study, a graft surveillance program utilizing angioplasty resulted in a decrease in thrombosis rate from 48 to 17 percent over a six year period [",
"      <a class=\"abstract\" href=\"UTD.htm?17/37/18010/abstract/25\">",
"       25",
"      </a>",
"      ]. Repeated angioplasty treatments were required. Their unassisted patency rate was 23 percent, while the assisted patency rate at one year was 68 percent.",
"     </li>",
"     <li>",
"      In a third study, 21 patients with greater than 50 percent stenosis of a functioning prosthetic bridge graft who had never undergone any procedure following graft placement were prospectively randomized to either no treatment (13 cases) or angioplasty (8 cases) [",
"      <a class=\"abstract\" href=\"UTD.htm?17/37/18010/abstract/53\">",
"       53",
"      </a>",
"      ]. In the treatment group, there was a statistically significant prolongation of patency, and decrease in thrombosis rate (0.10 versus 0.44 per patient-dialysis year for no treatment). The active therapy group received an average of 3.4 angioplasty treatments per patient.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, some evidence exists suggesting that the correction of prospectively detected stenosis with percutaneous transluminal angioplasty does not provide clear benefits [",
"    <a class=\"abstract\" href=\"UTD.htm?17/37/18010/abstract/54-56\">",
"     54-56",
"    </a>",
"    ]. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study, 112 hemodialysis patients were randomly assigned to monthly vascular access blood flow surveillance plus standard surveillance (dynamic venous pressure and physical examination) or standard surveillance alone, with only the blood flow group referred for angiography and angioplasty for stenosis greater than 50 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?17/37/18010/abstract/54\">",
"       54",
"      </a>",
"      ]. The time to graft thrombosis or time to graft loss was no different between the groups, suggesting that prospective monitoring plus preemptive angioplasty fails to provide significant benefit.",
"     </li>",
"     <li>",
"      In a second report, 64 patients monitored with monthly static venous",
"      <span class=\"nowrap\">",
"       pressure/systolic",
"      </span>",
"      blood pressure ratios were randomly assigned to either observation or an intervention group who underwent angiography and repair of identified stenoses if the monthly ratio was elevated (&ge;0.4) [",
"      <a class=\"abstract\" href=\"UTD.htm?17/37/18010/abstract/56\">",
"       56",
"      </a>",
"      ]. By comparison, repair in the observation group only occurred with thrombosis of access dysfunction. Graft survival was similar in both groups.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Some reasons for the discrepant findings relating to access survival with preemptive angioplasty include the relatively broad spectrum and severity of vascular lesions, patient variability, relatively small size of most studies, differences in blood flow and residual size achieved after angioplasty, and lack of standardization of the angioplasty procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?17/37/18010/abstract/57\">",
"     57",
"    </a>",
"    ]. To better address this issue, further study is required, particularly the adoption of a realistic standardization of how angioplasty is applied, and how outcomes and success are evaluated with the technique.",
"   </p>",
"   <p>",
"    Despite these conflicting findings, we recommend prospective monitoring for venous stenosis followed by angioplasty, if appropriate [",
"    <a class=\"abstract\" href=\"UTD.htm?17/37/18010/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h2\">",
"     Incidental stenosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 2006 National Kidney Foundation-Dialysis Outcomes Quality Initiative",
"    <span class=\"nowrap\">",
"     (NKF/DOQI",
"    </span>",
"    or",
"    <span class=\"nowrap\">",
"     K/DOQI)",
"    </span>",
"    hemodialysis access working group has emphasized the importance of the presence of evidence of a clinical or physiologic abnormality (eg, elevated venous pressure or decreased blood flow) prior to the treatment of a lesion [",
"    <a class=\"abstract\" href=\"UTD.htm?17/37/18010/abstract/24\">",
"     24",
"    </a>",
"    ]. The question arises as to what to do if an incidental stenosis with no associated clinical or physiological abnormalities is encountered during the conduct of an angiogram being performed for another indication. This is particularly likely to occur with central venous lesions.",
"   </p>",
"   <p>",
"    This was evaluated in a study of 35 patients with asymptomatic central venous stenosis [",
"    <a class=\"abstract\" href=\"UTD.htm?17/37/18010/abstract/58\">",
"     58",
"    </a>",
"    ]. Of these, 72 percent received treatment with angioplasty, while the remainder were untreated. The mean degree of stenosis in the treated group was 74 percent (range 50 to 100 percent) before and 40 percent (range, 0 to 75 percent) immediately after treatment. In the period following treatment, one patient developed arm swelling, four required stents, and four developed additional central venous stenosis. The mean degree of stenosis in the untreated group was 72 percent (range, 30 to 100 percent). No untreated patient progressed to symptoms, stent placement, or additional central venous stenosis. These findings, although derived from a preliminary small study, suggest that these asymptomatic lesions should be left alone.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?9/26/9635?source=see_link\">",
"       \"Patient information: Dialysis or kidney transplantation &mdash; which is right for me? (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?39/57/40852?source=see_link\">",
"       \"Patient information: Hemodialysis (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients receiving hemodialysis via a prosthetic graft dialysis access should be monitored prospectively for the development of venous stenosis. When such procedures suggest the presence of a stenotic lesion, the patient should be evaluated with angiography to determine if an anatomically significant lesion is actually present. Lesions that represent 50 percent stenosis or greater should be treated.",
"   </p>",
"   <p>",
"    Angioplasty should be regarded as a standard option for the management of venous stenosis associated with dialysis access grafts; its use in an intensive graft maintenance protocol clearly increases graft longevity, and decreases thrombosis and graft replacement rates.",
"   </p>",
"   <p>",
"    The",
"    <span class=\"nowrap\">",
"     K/DOQI",
"    </span>",
"    guidelines recommend that there should be no more than a 30 percent residual stenosis following angioplasty; however, we recommend that the goal should be",
"    <strong>",
"     no",
"    </strong>",
"    residual stenosis following treatment.",
"   </p>",
"   <p>",
"    It is very important that clinical or physiologic abnormalities that were present prior to treatment be checked as early as practical following therapy. This should actually be regarded as the true gauge of success. These abnormalities should be resolved after the procedure.",
"   </p>",
"   <p>",
"    There should also be a 50 percent-unassisted patency rate at six months post-procedure. If angioplasty is required more than two times within three months, an alternative treatment should be considered.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/37/18010/abstract/1\">",
"      K/DOQI Clinical Practice Guidelines and Clinical Practice Recommendations 2006 Updates Hemodialysis adequacy Peritoneal Dialysis Adequacy Vascular Access. Am J Kidney Dis 2006; 48(Suppl 1):S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/37/18010/abstract/2\">",
"      Beathard GA. Percutaneous transvenous angioplasty in the treatment of vascular access stenosis. Kidney Int 1992; 42:1390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/37/18010/abstract/3\">",
"      Kanterman RY, Vesely TM, Pilgram TK, et al. Dialysis access grafts: anatomic location of venous stenosis and results of angioplasty. Radiology 1995; 195:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/37/18010/abstract/4\">",
"      Gray RJ. Percutaneous intervention for permanent hemodialysis access: a review. J Vasc Interv Radiol 1997; 8:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/37/18010/abstract/5\">",
"      Vesely, TM. Percutaneous transluminal angioplasty for the treatment of failing hemodialysis grafts and fistulae. Semin Dial 1998; 11:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/37/18010/abstract/6\">",
"      Pappas JN, Vesely TM. Vascular rupture during angioplasty of hemodialysis raft-related stenoses. J Vasc Access 2002; 3:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/37/18010/abstract/7\">",
"      Beathard GA. Management of complications of endovascular dialysis access procedures. Semin Dial 2003; 16:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/37/18010/abstract/8\">",
"      Beathard GA, Litchfield T, Physician Operators Forum of RMS Lifeline, Inc. Effectiveness and safety of dialysis vascular access procedures performed by interventional nephrologists. Kidney Int 2004; 66:1622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/37/18010/abstract/9\">",
"      Beathard GA. Angioplasty for arteriovenous grafts and fistulae. Semin Nephrol 2002; 22:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/37/18010/abstract/10\">",
"      Khan FA, Vesely TM. Arterial problems associated with dysfunctional hemodialysis grafts: evaluation of patients at high risk for arterial disease. J Vasc Interv Radiol 2002; 13:1109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/37/18010/abstract/11\">",
"      Asif A, Gadalean FN, Merrill D, et al. Inflow stenosis in arteriovenous fistulas and grafts: a multicenter, prospective study. Kidney Int 2005; 67:1986.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/37/18010/abstract/12\">",
"      Duijm LE, Liem YS, van der Rijt RH, et al. Inflow stenoses in dysfunctional hemodialysis access fistulae and grafts. Am J Kidney Dis 2006; 48:98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/37/18010/abstract/13\">",
"      Taal MW, Chesterton LJ, McIntyre CW. Venography at insertion of tunnelled internal jugular vein dialysis catheters reveals significant occult stenosis. Nephrol Dial Transplant 2004; 19:1542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/37/18010/abstract/14\">",
"      Roy-Chaudhury P, Kelly BS, Miller MA, et al. Venous neointimal hyperplasia in polytetrafluoroethylene dialysis grafts. Kidney Int 2001; 59:2325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/37/18010/abstract/15\">",
"      Roy-Chaudhury P, Kelly BS, Zhang J, et al. Hemodialysis vascular access dysfunction: from pathophysiology to novel therapies. Blood Purif 2003; 21:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/37/18010/abstract/16\">",
"      Hemodialysis Clinical Practice Guidelines for the Canadian Society of Nephrology. J Am Soc Nephrol 2006; 17(Suppl 1):S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/37/18010/abstract/17\">",
"      Beathard, GA. Physical examination of the dialysis vascular access. Semin Dial 1998; 11:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/37/18010/abstract/18\">",
"      Turmel-Rodrigues L, Pengloan J, Baudin S, et al. Treatment of stenosis and thrombosis in haemodialysis fistulas and grafts by interventional radiology. Nephrol Dial Transplant 2000; 15:2029.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/37/18010/abstract/19\">",
"      Trerotola SO, Stavropoulos SW, Shlansky-Goldberg R, et al. Hemodialysis-related venous stenosis: treatment with ultrahigh-pressure angioplasty balloons. Radiology 2004; 231:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/37/18010/abstract/20\">",
"      Vesely TM, Siegel JB. Use of the peripheral cutting balloon to treat hemodialysis-related stenoses. J Vasc Interv Radiol 2005; 16:1593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/37/18010/abstract/21\">",
"      Kariya S, Tanigawa N, Kojima H, et al. Primary patency with cutting and conventional balloon angioplasty for different types of hemodialysis access stenosis. Radiology 2007; 243:578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/37/18010/abstract/22\">",
"      Vesely TM. Use of a purse string suture to close a percutaneous access site after hemodialysis graft interventions. J Vasc Interv Radiol 1998; 9:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/37/18010/abstract/23\">",
"      Lilly RZ, Carlton D, Barker J, et al. Predictors of arteriovenous graft patency after radiologic intervention in hemodialysis patients. Am J Kidney Dis 2001; 37:945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/37/18010/abstract/24\">",
"      K/DOQI Clinical Practice Guidelines and Clinical Practice Recommendations 2006 Updates Hemodialysis adequacy Peritoneal Dialysis Adequacy Vascular Access. Am J Kidney Dis 2006; 48 Suppl 1:S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/37/18010/abstract/25\">",
"      Funaki B, Kim R, Lorenz J, et al. Using pullback pressure measurements to identify venous stenoses persisting after successful angioplasty in failing hemodialysis grafts. AJR Am J Roentgenol 2002; 178:1161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/37/18010/abstract/26\">",
"      Maya ID, Oser R, Saddekni S, et al. Vascular access stenosis: comparison of arteriovenous grafts and fistulas. Am J Kidney Dis 2004; 44:859.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/37/18010/abstract/27\">",
"      Schwab SJ, Oliver MJ, Suhocki P, McCann R. Hemodialysis arteriovenous access: detection of stenosis and response to treatment by vascular access blood flow. Kidney Int 2001; 59:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/37/18010/abstract/28\">",
"      van der Linden J, Smits JH, Assink JH, et al. Short- and long-term functional effects of percutaneous transluminal angioplasty in hemodialysis vascular access. J Am Soc Nephrol 2002; 13:715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/37/18010/abstract/29\">",
"      Ahya SN, Windus DW, Vesely TM. Flow in hemodialysis grafts after angioplasty: Do radiologic criteria predict success? Kidney Int 2001; 59:1974.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/37/18010/abstract/30\">",
"      Murray BM, Herman A, Mepani B, Rajczak S. Access flow after angioplasty predicts subsequent arteriovenous graft survival. J Vasc Interv Radiol 2006; 17:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/37/18010/abstract/31\">",
"      Glanz S, Gordon DH, Butt KM, et al. The role of percutaneous angioplasty in the management of chronic hemodialysis fistulas. Ann Surg 1987; 206:777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/37/18010/abstract/32\">",
"      Hunter DW, So SK. Dialysis access: radiographic evaluation and management. Radiol Clin North Am 1987; 25:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/37/18010/abstract/33\">",
"      Safa AA, Valji K, Roberts AC, et al. Detection and treatment of dysfunctional hemodialysis access grafts: effect of a surveillance program on graft patency and the incidence of thrombosis. Radiology 1996; 199:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/37/18010/abstract/34\">",
"      Sugimoto K, Higashino T, Kuwata Y, et al. Percutaneous transluminal angioplasty of malfunctioning Brescia-Cimino arteriovenous fistula: analysis of factors adversely affecting long-term patency. Eur Radiol 2003; 13:1615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/37/18010/abstract/35\">",
"      Castellan L, Miotto D, Savastano S, et al. [The percutaneous transluminal angioplasty of Brescia-Cimino arteriovenous fistulae. An evaluation of the results]. Radiol Med 1994; 87:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/37/18010/abstract/36\">",
"      Lay JP, Ashleigh RJ, Tranconi L, et al. Result of angioplasty of brescia-cimino haemodialysis fistulae: medium-term follow-up. Clin Radiol 1998; 53:608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/37/18010/abstract/37\">",
"      Bohndorf K, G&uuml;nther RW, Vorwerk D, et al. Technical aspects and results of percutaneous transluminal angioplasty in Brescia-Cimino dialysis fistulas. Cardiovasc Intervent Radiol 1990; 13:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/37/18010/abstract/38\">",
"      Longwitz D, Pham TH, Heckemann RG, Hecking E. [Angioplasty in the stenosed hemodialysis shunt: experiences with 100 patients and 166 interventions]. Rofo 1998; 169:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/37/18010/abstract/39\">",
"      Guerra A, Raynaud A, Beyssen B, et al. Arterial percutaneous angioplasty in upper limbs with vascular access devices for haemodialysis. Nephrol Dial Transplant 2002; 17:843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/37/18010/abstract/40\">",
"      Davidson CJ, Newman GE, Sheikh KH, et al. Mechanisms of angioplasty in hemodialysis fistula stenoses evaluated by intravascular ultrasound. Kidney Int 1991; 40:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/37/18010/abstract/41\">",
"      Alexander J, Hood D, Rowe V, et al. Does surgical intervention significantly prolong the patency of failed angioaccess grafts previously treated with percutaneous techniques? Ann Vasc Surg 2002; 16:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/37/18010/abstract/42\">",
"      Sacks D, McClenny TE, Cardella JF, Lewis CA. Society of Interventional Radiology clinical practice guidelines. J Vasc Interv Radiol 2003; 14:S199.",
"     </a>",
"    </li>",
"    <li>",
"     Beathard, GA, Litchfield, T. Physician Operators Forum of RMS Lifeline, Inc. Effectiveness and safety of dialysis vascular access procedures performed by interventional nephrologists. Kidney Int (publication pending).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/37/18010/abstract/44\">",
"      Beathard GA. The treatment of vascular access graft dysfunction: a nephrologist's view and experience. Adv Ren Replace Ther 1994; 1:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/37/18010/abstract/45\">",
"      Funaki B, Szymski GX, Leef JA, et al. Wallstent deployment to salvage dialysis graft thrombolysis complicated by venous rupture: early and intermediate results. AJR Am J Roentgenol 1997; 169:1435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/37/18010/abstract/46\">",
"      Rundback JH, Leonardo RF, Poplausky MR, Rozenblit G. Venous rupture complicating hemodialysis access angioplasty: percutaneous treatment and outcomes in seven patients. AJR Am J Roentgenol 1998; 171:1081.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/37/18010/abstract/47\">",
"      Raynaud AC, Angel CY, Sapoval MR, et al. Treatment of hemodialysis access rupture during PTA with Wallstent implantation. J Vasc Interv Radiol 1998; 9:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/37/18010/abstract/48\">",
"      Sofocleous CT, Schur I, Koh E, et al. Percutaneous treatment of complications occurring during hemodialysis graft recanalization. Eur J Radiol 2003; 47:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/37/18010/abstract/49\">",
"      Burger, H, Zijlstra, JJ, Kluchert, SA, et al. Percutaneous transluminal angioplasty improves longevity in fistulae and shunts for hemodialysis. Nephrol Dial Transplant 1990; 5:608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/37/18010/abstract/50\">",
"      Schwab SJ, Raymond JR, Saeed M, et al. Prevention of hemodialysis fistula thrombosis. Early detection of venous stenoses. Kidney Int 1989; 36:707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/37/18010/abstract/51\">",
"      Besarab A, Dorrell S, Moritz M, et al. Determinants of measured dialysis venous pressure and its relationship to true intra-access venous pressure. ASAIO Trans 1991; 37:M270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/37/18010/abstract/52\">",
"      Besarab A, Sullivan KL, Ross RP, Moritz MJ. Utility of intra-access pressure monitoring in detecting and correcting venous outlet stenoses prior to thrombosis. Kidney Int 1995; 47:1364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/37/18010/abstract/53\">",
"      Martin LG, MacDonald MJ, Kikeri D, et al. Prophylactic angioplasty reduces thrombosis in virgin ePTFE arteriovenous dialysis grafts with greater than 50% stenosis: subset analysis of a prospectively randomized study. J Vasc Interv Radiol 1999; 10:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/37/18010/abstract/54\">",
"      Moist LM, Churchill DN, House AA, et al. Regular monitoring of access flow compared with monitoring of venous pressure fails to improve graft survival. J Am Soc Nephrol 2003; 14:2645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/37/18010/abstract/55\">",
"      Ram SJ, Work J, Caldito GC, et al. A randomized controlled trial of blood flow and stenosis surveillance of hemodialysis grafts. Kidney Int 2003; 64:272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/37/18010/abstract/56\">",
"      Dember LM, Holmberg EF, Kaufman JS. Randomized controlled trial of prophylactic repair of hemodialysis arteriovenous graft stenosis. Kidney Int 2004; 66:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/37/18010/abstract/57\">",
"      White JJ, Bander SJ, Schwab SJ, et al. Is percutaneous transluminal angioplasty an effective intervention for arteriovenous graft stenosis? Semin Dial 2005; 18:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/37/18010/abstract/58\">",
"      Levit RD, Cohen RM, Kwak A, et al. Asymptomatic central venous stenosis in hemodialysis patients. Radiology 2006; 238:1051.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1910 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-118.195.65.244-3BAB8F1ACB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_37_18010=[""].join("\n");
var outline_f17_37_18010=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H40\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GENERAL ISSUES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Surgical therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Percutaneous angioplasty",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      LOCATION OF LESIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      DIAGNOSTIC CRITERIA FOR STENOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      NATURE OF LESIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      ANGIOPLASTY THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Procedure",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Pre-procedure evaluation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Accessing the graft",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Preprocedure angiogram",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Passing guidewire",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Balloon introduction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Angioplasty",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Ultrahigh pressure balloons",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Cutting angioplasty balloon",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Post-procedure evaluation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Hemostasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      JUDGING THE SUCCESS OF ANGIOPLASTY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Anatomic criteria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Clinical criteria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Hemodynamic/physiologic criteria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      PATENCY RATES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      SPECIAL CONSIDERATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Character of the lesion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Recurrent lesions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Frequent recurrences",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Use of endoluminal stent",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Surgical revision",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      PROCEDURE RELATED COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Subclinical extravasation of contrast",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Hematomas",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      - Grade 1",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      - Grade 2",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      - Grade 3",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      BENEFITS OF PROSPECTIVE TREATMENT OF VENOUS STENOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      Incidental stenosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H40\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"SURG/1910\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/1910|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?1/28/1472\" title=\"diagnostic image 1\">",
"      8mmx8cm angioplasty balloon",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?14/62/15328\" title=\"diagnostic image 2\">",
"      Stenosis venous anastomosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?21/34/22063\" title=\"diagnostic image 3\">",
"      Stenosis basilic vein",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?35/34/36399\" title=\"diagnostic image 4\">",
"      Stenosis subclavian vein",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/1910|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?27/20/27972\" title=\"picture 1\">",
"      Neointimal hyperplasia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?9/29/9695\" title=\"picture 2\">",
"      Intra-graft stenosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/32/39432?source=related_link\">",
"      Central vein stenosis associated with dialysis access",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/50/27429?source=related_link\">",
"      Monitoring and surveillance of hemodialysis arteriovenous fistulas to prevent thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/38/615?source=related_link\">",
"      Monitoring and surveillance of hemodialysis arteriovenous grafts to prevent thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/22/31082?source=related_link\">",
"      Nephrogenic systemic fibrosis/nephrogenic fibrosing dermopathy in advanced renal failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/21/16727?source=related_link\">",
"      Overview of the treatment of stenosis and thrombotic complications of hemodialysis arteriovenous grafts and fistulas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?9/26/9635?source=related_link\">",
"      Patient information: Dialysis or kidney transplantation &mdash; which is right for me? (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?39/57/40852?source=related_link\">",
"      Patient information: Hemodialysis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/48/7942?source=related_link\">",
"      Strategies other than treatment of stenosis to prevent thrombosis of hemodialysis vascular access grafts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/42/11944?source=related_link\">",
"      Use of stents for venous stenosis associated with dialysis vascular access",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_37_18011="Stillbirth rate after amnio";
var content_f17_37_18011=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F64831&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F64831&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Stillbirth rate after amniocentesis in series utilizing ultrasound guidance during the procedure",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Author",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Stillbirths",
"       </td>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Difference in rates (95% confidence interval)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Cases (numbers)",
"       </td>",
"       <td class=\"subtitle2\">",
"        Controls (number)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tabor (1986)",
"       </td>",
"       <td>",
"        0.4% (10/2264)",
"       </td>",
"       <td>",
"        0.5% (12/2287)",
"       </td>",
"       <td>",
"        -0.1% (-0.4%; 0.3%)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tongsong (1998)",
"       </td>",
"       <td>",
"        1.4% (29/2009)",
"       </td>",
"       <td>",
"        1.4% (28/2016)",
"       </td>",
"       <td>",
"        0.1% (-0.7%; 0.8%)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Antsaklis (2000)",
"       </td>",
"       <td>",
"        0.6% (22/3617)",
"       </td>",
"       <td>",
"        0.5% (27/5244)",
"       </td>",
"       <td>",
"        0.1% (-0.2%; 0.4%)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    The stillbirth rate was calculated among continuing pregnancies, and it was not significantly different in amniocentesis cases compared with controls. The rates of preterm delivery, premature rupture of membranes, neonatal mortality and perinatal mortality were not different between cases and controls (data not shown).",
"    <div class=\"footnotes\">",
"     %: percent.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_37_18011=[""].join("\n");
var outline_f17_37_18011=null;
var title_f17_37_18012="Tubal neoplasia rrBSO specimens";
var content_f17_37_18012=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F86928&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F86928&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Frequency of serous fallopian tubal intraepithelial carcinoma (STIC) in risk reducing salpingo-oophorectomy specimens of women with BRCA mutations",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"4\" width=\"25%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Author",
"       </td>",
"       <td class=\"subtitle1\">",
"        n",
"       </td>",
"       <td class=\"subtitle1\">",
"        <p>",
"         Pelvic serous neoplasm",
"        </p>",
"        <p>",
"         n (percent)",
"        </p>",
"       </td>",
"       <td class=\"subtitle1\">",
"        <p>",
"         Tubal involvement",
"        </p>",
"        <p>",
"         n (percent)",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Colgan 2001",
"       </td>",
"       <td class=\"centered\">",
"        39",
"       </td>",
"       <td class=\"centered\">",
"        5 (13)",
"       </td>",
"       <td class=\"centered\">",
"        4 (80)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Leeper 2002",
"       </td>",
"       <td class=\"centered\">",
"        30",
"       </td>",
"       <td class=\"centered\">",
"        5 (17)",
"       </td>",
"       <td class=\"centered\">",
"        3 (60)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Powell 2005",
"       </td>",
"       <td class=\"centered\">",
"        67",
"       </td>",
"       <td class=\"centered\">",
"        7 (10)",
"       </td>",
"       <td class=\"centered\">",
"        4 (57)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Carcangiu 2006",
"       </td>",
"       <td class=\"centered\">",
"        50",
"       </td>",
"       <td class=\"centered\">",
"        6 (12)",
"       </td>",
"       <td class=\"centered\">",
"        4 (67)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Finch 2006",
"       </td>",
"       <td class=\"centered\">",
"        159",
"       </td>",
"       <td class=\"centered\">",
"        7 (4)",
"       </td>",
"       <td class=\"centered\">",
"        6 (86)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Callahan 2007",
"       </td>",
"       <td class=\"centered\">",
"        100",
"       </td>",
"       <td class=\"centered\">",
"        7 (7)",
"       </td>",
"       <td class=\"centered\">",
"        7 (100)",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        Hirst 2009",
"       </td>",
"       <td class=\"centered\">",
"        45",
"       </td>",
"       <td class=\"centered\">",
"        4 (9)",
"       </td>",
"       <td class=\"centered\">",
"        4 (100)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Total",
"        </strong>",
"       </td>",
"       <td class=\"centered\">",
"        <strong>",
"         490",
"        </strong>",
"       </td>",
"       <td class=\"centered\">",
"        <strong>",
"         41 (8)",
"        </strong>",
"       </td>",
"       <td class=\"centered\">",
"        <strong>",
"         32 (78)",
"        </strong>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_37_18012=[""].join("\n");
var outline_f17_37_18012=null;
var title_f17_37_18013="Transverse relaxation in MRI";
var content_f17_37_18013=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F62262&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F62262&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Transverse relaxation in MRI",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 338px; height: 204px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Evolution of transverse magnetization following a 90&deg; radiofrequency excitation. There is maximal alignment of magnetization vectors at time t=0 immediately after excitation. Vectors have lost phase coherence at time t=T",
"    <sub>",
"     2",
"    </sub>",
"    . At time t&gt;&gt;T",
"    <sub>",
"     2",
"    </sub>",
"    , the magnetization vectors are randomly distributed and no macroscopic signal can be measured.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_37_18013=[""].join("\n");
var outline_f17_37_18013=null;
var title_f17_37_18014="Framingham risk score men";
var content_f17_37_18014=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F67655&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F67655&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Framingham risk score for men*",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"3\" rowspan=\"1\">",
"        Age",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"3\" rowspan=\"1\">",
"        Diabetes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Years",
"       </td>",
"       <td class=\"subtitle2\" colspan=\"2\" rowspan=\"1\">",
"        Points",
"       </td>",
"       <td class=\"subtitle2\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle2\" colspan=\"2\" rowspan=\"1\">",
"        Points&nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\">",
"        30-34",
"       </td>",
"       <td colspan=\"2\" rowspan=\"1\">",
"        -1",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td colspan=\"2\" rowspan=\"1\">",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\">",
"        35-39",
"       </td>",
"       <td colspan=\"2\" rowspan=\"1\">",
"        0",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td colspan=\"2\" rowspan=\"1\">",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\">",
"        40-44",
"       </td>",
"       <td colspan=\"2\" rowspan=\"1\">",
"        1",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"3\" rowspan=\"1\">",
"        Smoker",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\">",
"        45-49",
"       </td>",
"       <td colspan=\"2\" rowspan=\"1\">",
"        2",
"       </td>",
"       <td class=\"subtitle2\">",
"        &nbsp;&nbsp;",
"       </td>",
"       <td class=\"subtitle2\" colspan=\"2\" rowspan=\"1\">",
"        Points",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\">",
"        50-54",
"       </td>",
"       <td colspan=\"2\" rowspan=\"1\">",
"        3",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td colspan=\"2\" rowspan=\"1\">",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\">",
"        55-59",
"       </td>",
"       <td colspan=\"2\" rowspan=\"1\">",
"        4",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td colspan=\"2\" rowspan=\"1\">",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\">",
"        60-64",
"       </td>",
"       <td colspan=\"2\" rowspan=\"1\">",
"        5",
"       </td>",
"       <td colspan=\"3\" rowspan=\"3\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\">",
"        65-69",
"       </td>",
"       <td colspan=\"2\" rowspan=\"1\">",
"        6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\">",
"        70-74",
"       </td>",
"       <td colspan=\"2\" rowspan=\"1\">",
"        7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"3\" rowspan=\"1\">",
"        LDL-C",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"3\" rowspan=\"1\">",
"        HDL-C",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        mg/dL",
"       </td>",
"       <td class=\"subtitle2\" colspan=\"1\">",
"        mmol/L",
"       </td>",
"       <td class=\"subtitle2\">",
"        Points",
"       </td>",
"       <td class=\"subtitle2\">",
"        mg/dL",
"       </td>",
"       <td class=\"subtitle2\">",
"        mmol/L",
"       </td>",
"       <td class=\"subtitle2\">",
"        Points",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &lt;100",
"       </td>",
"       <td>",
"        &lt;2.59",
"       </td>",
"       <td>",
"        -3",
"       </td>",
"       <td>",
"        &lt;35",
"       </td>",
"       <td>",
"        &lt;0.90",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        100-129",
"       </td>",
"       <td colspan=\"1\">",
"        2.60-3.36",
"       </td>",
"       <td colspan=\"1\">",
"        0",
"       </td>",
"       <td colspan=\"1\">",
"        35-44",
"       </td>",
"       <td>",
"        0.91-1.16",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        130-159",
"       </td>",
"       <td colspan=\"1\">",
"        3.37-4.14",
"       </td>",
"       <td colspan=\"1\">",
"        0",
"       </td>",
"       <td colspan=\"1\">",
"        45-49",
"       </td>",
"       <td>",
"        1.17-1.29",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        160-190",
"       </td>",
"       <td colspan=\"1\">",
"        4.50-4.92",
"       </td>",
"       <td colspan=\"1\">",
"        1",
"       </td>",
"       <td colspan=\"1\">",
"        50-54",
"       </td>",
"       <td>",
"        1.30-1.55",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &gt;190",
"       </td>",
"       <td>",
"        &gt;4.92",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        &gt;60",
"       </td>",
"       <td>",
"        &gt;1.56",
"       </td>",
"       <td>",
"        -1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Systolic blood pressure, mmHg",
"       </td>",
"       <td class=\"subtitle1\">",
"        Diastolic &lt;80 mmHg",
"       </td>",
"       <td class=\"subtitle1\">",
"        Diastolic 80-84",
"       </td>",
"       <td class=\"subtitle1\">",
"        Diastolic 85-89",
"       </td>",
"       <td class=\"subtitle1\">",
"        Diastolic 90-99",
"       </td>",
"       <td class=\"subtitle1\">",
"        Diastolic &ge;100",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &lt;120",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        120-129",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        130-139",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        140-159",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &ge;160",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"6\" rowspan=\"1\">",
"        Coronary",
"heart disease (CHD) risk",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Total points",
"       </td>",
"       <td class=\"subtitle2\" colspan=\"2\" rowspan=\"1\">",
"        10 yr CHD risk, percent",
"       </td>",
"       <td class=\"subtitle2\">",
"        Total points",
"       </td>",
"       <td class=\"subtitle2\" colspan=\"2\" rowspan=\"1\">",
"        10 yr CHD risk, percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &lt;-3",
"       </td>",
"       <td colspan=\"2\" rowspan=\"1\">",
"        1",
"       </td>",
"       <td>",
"        6",
"       </td>",
"       <td colspan=\"2\" rowspan=\"1\">",
"        11",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        -2",
"       </td>",
"       <td colspan=\"2\" rowspan=\"1\">",
"        2",
"       </td>",
"       <td>",
"        7",
"       </td>",
"       <td colspan=\"2\" rowspan=\"1\">",
"        14",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        -1",
"       </td>",
"       <td colspan=\"2\" rowspan=\"1\">",
"        2",
"       </td>",
"       <td>",
"        8",
"       </td>",
"       <td colspan=\"2\" rowspan=\"1\">",
"        18",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        0",
"       </td>",
"       <td colspan=\"2\" rowspan=\"1\">",
"        3",
"       </td>",
"       <td>",
"        9",
"       </td>",
"       <td colspan=\"2\" rowspan=\"1\">",
"        22",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1",
"       </td>",
"       <td colspan=\"2\" rowspan=\"1\">",
"        4",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td colspan=\"2\" rowspan=\"1\">",
"        27",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2",
"       </td>",
"       <td colspan=\"2\" rowspan=\"1\">",
"        5",
"       </td>",
"       <td>",
"        11",
"       </td>",
"       <td colspan=\"2\" rowspan=\"1\">",
"        33",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3",
"       </td>",
"       <td colspan=\"2\" rowspan=\"1\">",
"        6",
"       </td>",
"       <td>",
"        12",
"       </td>",
"       <td colspan=\"2\" rowspan=\"1\">",
"        40",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4",
"       </td>",
"       <td colspan=\"2\" rowspan=\"1\">",
"        7",
"       </td>",
"       <td>",
"        13",
"       </td>",
"       <td colspan=\"2\" rowspan=\"1\">",
"        47",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        5",
"       </td>",
"       <td colspan=\"2\" rowspan=\"1\">",
"        9",
"       </td>",
"       <td>",
"        14",
"       </td>",
"       <td colspan=\"2\" rowspan=\"1\">",
"        56",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Framingham risk scoring system for men. Use to calculate the risk of developing clinical coronary heart disease (CHD) in men who do not have known CHD. Clinical CHD includes angina pectoris, recognized or unrecognized myocardial infarction (MI), coronary insufficiency (prolonged chest discomfort associated with transient repolarization abnormalities without criteria for MI), or CHD death.",
"     <br>",
"      To calculate the Framingham risk estimate, add points for age, presence of diabetes, smoking status, LDL-cholesterol (LDL-C), HDL-cholesterol (HDL-C), and blood pressure. Find the total point score on the bottom table to determine the 10-year risk of CHD.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Adapted with permission from Wilson PW, D'Agostino R, Levy D, et al. Prediction of coronary heart disease using risk factor categories. Circulation 1998; 97:1837. Copyright &copy; 1998 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_37_18014=[""].join("\n");
var outline_f17_37_18014=null;
var title_f17_37_18015="Pulmonary function in pregnancy";
var content_f17_37_18015=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F80850&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F80850&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 572px\">",
"   <div class=\"ttl\">",
"    Changes in pulmonary function tests during pregnancy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 552px; height: 336px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Serial measurements of lung volume compartments during pregnancy. Functional residual capacity decreases approximately 20 percent during the latter half of pregnancy, due to a decrease in both expiratory reserve volume and residual volume.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Redrawn from Prowse, CM, Gaensler, EA, Anesthesiology 1965; 26:381.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_37_18015=[""].join("\n");
var outline_f17_37_18015=null;
